

IASO

PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

INTERIM FINANCIAL STATEMENTS

Of the period January 1st - March 31st 2009

In accordance with IFRS

Distinctive Title: IASO S.A.

37-39 Kifissias Ave., Maroussi

S.A. Registration No: 13366/06/B/86/61

www.iaso.gr

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 1 of 57

	Statement of Financial Position of the Group and the Company as at 31/03/20094
	Statement of Comprehensive Income of the Group and the Company as at 31/03/2009
	Cash Flow Statement of the Group and the Company as at 31/03/20096
D.	Statement of Changes in Equity of the Group and the Company as at 31/03/2009 7
E.	Notes to the Financial Statements8
1.	General information8
2.	Summary of significant accounting policies8
	2.1 Basis of preparation of the financial statements
	2.2 Consolidation
	2.3 Segment reporting
	2.4 Foreign currency conversion
	2.5 Property, plant and equipment
	2.6 Intangible assets
	2.7 Construction contracts
	2.8 Investments
	2.9 Inventories
	2.10 Trade receivables
	2.11 Cash and cash equivalents
	2.12 Share capital
	2.13 Borrowings
	2.14 Deferred income tax
	2.15 Employee benefits
	2.16 Provisions
	2.17 Revenue recognition
	2.18 Leases
	2.19 Dividend distribution
	2.20 Government grants
3.	Financial risk management
	3.1 Fair value estimation 27
	3.2 Financial risk
4.	Critical accounting estimates and judgements

	4.1 Critical accounting estimates and assumptions	28
5.	Information by business unit	28
6.	Property, plant and equipment	32
7.	Intangible assets	35
8.	Inter-company transactions	37
	8.1 Inter-company transactions	37
	8.2 Investments to subsidiaries	38
9.	Available-for-sale financial assets	40
10.	Other financial assets at fair value through profit or loss	41
11.	Trade and other receivables	41
12.	Inventories	41
13.	Cash and cash equivalents	42
14.	Borrowings	42
	14.1 Net borrowings	44
15.	Trade and other payables	45
16.	Retirement benefit obligations	46
17.	Other gains	47
18.	Finance costs – net	47
19.	Income tax expense	48
20.	Earnings per share	49
21.	Dividends per share	50
22.	Expenses by nature	50
23.	Guarantees	52
24.	Share capital	53
25.	Other long-term receivables	53
26.	Other non-current liabilities	54
27.	Other non-current provisions	54
28.	Other operating expenses	54
29.	Reserves at fair value- Other reserves	55
30.	Events after the balance sheet date	55
F. I	Data and Information for the period January 1 st to March 31 st 2009	57

A. STATEMENT OF FINANCIAL POSITION OF THE GROUP AND THE COMPANY AS AT 31/03/2009

ASSETS	Note	THE GROUP 31/03/2009	THE GROUP 31/12/2008	THE COMPANY 31/03/2009	THE COMPANY 31/12/2008
Non-current assets					
Property, plant and equipment	6	268.930.670,52	261.990.376,40	129.855.457,64	129.530.544,09
Intangible assets	7	1.485.663,37	1.556.846,35	976.638,52	1.012.669,45
Investments in subsidiaries	8.2	0,00	0,00	124.485.731,36	121.985.730,36
Other long-term receivables	25	851.395,54	805.761,35	75.748,04	74.932,04
		271,267,729,43	264.352.984,10	255.393.575,56	252.603.875,94
Current assets		Í	,	,	,
Inventories	12	5.289.271,17	5.465.581,38	2.885.708,22	2.753.862,66
Trade receivables	11	37.354.400,01	34.866.199,56	5.243.392,16	5.374.029,81
Other receivables	11	13.903.628,65	12.154.759,03	9.901.376,65	11.318.837,08
Available-for-sale financial assets	9	4.189.927,64	4.189.927,64	4.189.927,64	4.189.927,64
Other financial assets at fair value through profit or loss	10	340.135,38	363.916,07	340.135,38	363.916,07
Cash and cash equivalents	13	21.967.322,79	23.362.891,30	6.992.231,85	6.157.697,72
1		83.044.685,64	80.403.274,98	29.552.771,90	30.158.270,98
TOTAL ASSETS		354.312.415,07	344.756.259,08	284.946.347,46	282.762.146,92
TOTAL MODELS		334.312.413,07	344.730.239,00	204.940.347,40	202.702.140,72
		THE CROUD	THE CROUD	THE COMPANY	THE COMPANY
I I A DIT TETTEC		THE GROUP 31/03/2009	THE GROUP 31/12/2008	THE COMPANY 31/03/2009	THE COMPANY 31/12/2008
LIABILITIES		31/03/2009	31/12/2008	31/03/2009	31/12/2008
EQUITY	2.4				
Share capital (53.155.053 shares x 0.44€)	24	23.388.223,32	23.388.223,32	23.388.223,32	23.388.223,32
Share premium account	24	42.497.459,83	42.497.459,83	42.497.459,83	42.497.459,83
Reserves at fair value	29	65.756.493,43	65.756.493,43	40.842.266,55	40.842.266,55
Other reserves	29	6.975.781,65	6.975.781,65	6.480.570,89	6.480.570,89
Retained earnings		-11.511.874,63	-18.051.089,12	55.625.383,15	49.671.980,46
Total equity of Company's equity holders		127.106.083,60	120.566.869,11	168.833.903,74	162.880.501,05
Minority interest	8.2	11.900.200,85	9.798.981,32	0,00	0,00
Total equity		139.006.304,45	130.365.850,43	168.833.903,74	162.880.501,05
LIABILITIES					
Non-current liabilities					
Borrowings	14	120.250.000,00	114.250.000,00	69.250.000,00	66.750.000,00
Deferred income tax liabilities	19	14.888.677,25	14.480.323,29	13.869.119,37	13.690.711,85
Retirement benefit obligations	16	4.494.281,03	4.761.022,27	2.850.605,89	3.024.056,90
Other non-current liabilities	26	4.837.840,65	4.554.611,76	73.354,75	68.854,75
Other non-current provisions	27	1.645.151,13	1.896.904,36	1.585.151,13	1.836.904,36
		146.115.950,06	139.942.861,68	87.628.230,94	85.370.527,86
Current liabilities		Í	ŕ	,	,
Trade and other payables	15	53.602.149,90	58.019.814,31	15.826.289,28	20.937.487,12
Current income tax liabilities	19	10.338.010,66	8.427.732,66	9.907.923,50	8.073.630,89
Short-term borrowings	14	5.250.000,00	8.000.000,00	2.750.000,00	5.500.000,00
-		69.190.160,56	74.447.546,97	28.484.212,78	34.511.118,01
Total Liabilities		215.306.110,62	214.390.408,65	116.112.443,72	119.881.645,87
Total Equity and Liabilities		354.312.415,07	344.756,259,08	284.946.347.46	282.762.146,92

Page 4 of 57

B. STATEMENT OF COMPREHENSIVE INCOME OF THE GROUP AND THE COMPANY AS AT 31/03/2009

	Note	THE C	THE GROUP		MPANY
		01/01-31/03/2009	01/01-31/03/2008	01/01-31/03/2009	01/01-31/03/2008
Sales	5	46.103.235,62	45.823.518,66	26.772.964,84	26.474.836,53
Cost of sales	22	34.527.291,63	33.182.106,18	17.728.195,94	16.374.516,14
Gross profit		11.575.943,99	12.641.412,48	9.044.768,90	10.100.320,39
Other operating income	17	1.407.768,10	757.514,53	995.950,96	481.160,31
Administrative expenses	22	-1.213.976,74	-1.192.329,84	-879.559,27	-754.391,56
Selling and marketing costs	22	-1.345.781,42	-881.408,65	-472.509,30	-463.654,74
Other operating expenses	28	-279.153,71	-489.376,44	-1.248,61	-18.569,88
Earnings before taxes, financing, investing results and depreciation – amortization (EBITDA)		12.346.228,58	12.690.549,82	9.948.793,93	10.293.048,14
Amortization – Depreciation	6,7,22	-2.201.428,35	-1.854.737,74	-1.261.391,25	-948.183,62
Earnings before taxes, financing, investing results (EBIT)		10.144.800,23	10.835.812,08	8.687.402,68	9.344.864,52
Finance costs – profit	18	122.356,69	237.243,74	32.857,03	93.458,26
Finance costs – expenses	18	-992.629,12	-1.742.003,85	-669.459,21	-964.564,07
Other finance results		0,00	0,00	0,00	0,00
Profit/loss from related parties		0,00	0,00	0,00	0,00
Profit before taxes		9.274.527,80	9.331.051,97	8.050.800,50	8.473.758,71
Income tax expense	19	-2.406.750,28	-2.450.007,30	-2.097.397,81	-2.205.683,99
Profit/Loss after taxes (A)		6.867.777,52	6.881.044,67	5.953.402,69	6.268.074,72
Attributable to:					
Equity holders of the Company	20	6.835.478,99	6.864.309,79	5.953.402,69	6.268.074,72
Minority interest (loss)		32.298,53	16.734,87	-	-
Other comprehensive income after taxes (B)		0,00	0,00	0,00	0,00
Total comprehensive income after taxes (A)+(B)		6.867.777,52	6.881.044,67	5.953.402,69	6.268.074,72
Attributable to:					
Equity holders of the Company		6.835.478,99	6.864.309,79	5.953.402,69	6.268.074,72
Minority interest (loss)		32.298,53	16.734,87	-	-
Profit/Loss after taxes per share – basic (expressed in $\mathfrak E$)	20	0,1286	0,1557	0,112	0,1422

Page 5 of 57

C. CASH FLOW STATEMENT OF THE GROUP AND THE COMPANY AS AT 31.03.2009

	THE GROUP		THE COMPANY		
	01/01-31/03/2009	01/01-31/03/2008	01/01-31/03/2009	01/01-31/03/2008	
Cash Flows from Operating Activities					
Profit for the period	9.274.527,80	9.331.051,97	8.050.800,50	8.473.758,71	
Adjustments to profit	5.198.553,60	5.876.679,55	2.994.909,14	2.919.638,37	
	14.473.081,40	15.207.731,52	11.045.709,64	11.393.397,08	
Adjustments of working capital					
Decrease/(increase) inventories	176.310,21	-148.567,42	-131.845,56	73.868,25	
Decrease/(increase) receivables	-2.911.659,65	-1.141.361,32	-113.834,39	-700.165,92	
Decrease/(increase) of other current assets	-40.090,85	-750.504,65	-816,00	-100.369,86	
Increase/(decrease) of payable accounts (except banks)	-7.603.856,82	-7.529.048,36	-6.737.374,52	-3.458.925,19	
Outflow of provisions	-272.629,67	0,00	-272.629,67	0,00	
-	-10.651.926,78	-9.569.481,75	-7.256.500,14	-4.185.592,72	
Net cash generated from operating activities	3.821.154,62	5.638.249,77	3.789.209,50	7.207.804,36	
Cash flows from operating Activities					
Interest paid	-1.156.620,20	-2.013.811,95	-1.073.046,41	-1.236.372,17	
Income tax paid	-173.974,14	-165.425,59	-164.854,14	-165.425,59	
Cash flow generated from (used in) Operating Activities (A)	2.490.560,28	3.459.012,23	2.551.308,95	5.806.006,60	
Cash flows from Investing Activities					
Purchase of property, plant and equipment (PPE)	-9.075.253,00	-5.316.587,74	-1.539.563,87	-196.377,96	
Purchases of intangible assets	-12.852,00	-6.435,23	-10.710,00	-6.435,23	
Disposal of PPE	6.300,00	5.398,72	0,00	5.398,72	
Purchases of Available-for-sale financial assets	0,00	0,00	0,00	0,00	
Purchases of financial assets at fair value					
through profit or loss	0,00	-46.470,40	-1,00	-4.450.608,68	
Adjustment of derivative financial assets	0,00	0,00	0,00	0,00	
Disposal of available-for-sale financial assets	0,00	0,00	0,00	0,00	
Disposal of financial assets at fair value through profit or loss	0,00	155.200,00	0,00	155.200,00	
Interest received	103.669,51	237.243,74	14.169,85	93.458,26	
Proceeds from repayments of borrowings from related parties	0,00	0,00	0,00	0,00	
Proceeds from grants	69.665,00	0,00	69.665,00	0,00	
Net cash generated from (used in) Investing Activities (B)	-8.908.470,49	-4.971.650,91	-1.466.440,02	-4.399.364,89	
Cash Flows from Financing Activities					
Share capital increase/ decrease	1.772.676,50	121.833,22	0,00	0,00	
Disposal of treasury shares	0,00	0,00	0,00	0,00	
Dividends paid to Company's shareholders	-334,80	-14.327,33	-334,80	-14.327,33	
Raised borrowings	6.000.000,00	7.000.000,00	2.500.000,00	0,00	
Repayments of borrowings	-2.750.000,00	-526.492,62	-2.750.000,00	0,00	
Payments of finance lease capital	0,00	0,00	0,00	0,00	
Net cash generated from (used in) Financing Activities (C)	5.022.341,70	6.581.013,27	-250.334,80	-14.327,33	
Net (decrease)/ increase in cash and cash equivalents (A+B+C) $$	-1.395.568,51	5.068.374,59	834.534,13	1.392.314,38	
Cash and cash equivalents at beginning of period	23.362.891,30	27.443.241,60	6.157.697,72	12.486.263,90	
Cash and cash equivalents at end of period	21.967.322,79	32.511.616,19	6.992.231,85	13.878.578,28	

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 6 of 57

D. STATEMENT OF CHANGES IN EQUITY OF THE GROUP AND THE COMPANY AS AT 31/03/2009

	THE G	ROUP	THE COMPANY		
	01/01-31/03/2009	01/01-31/03/2008	01/01-31/03/2009	01/01-31/03/2008	
Net equity of period Opening Balance (1/1/2009 and 1/1/2008 respectively)	130.365.850,43	120.218.021,80	162.880.501,05	152.835.972,74	
Comprehensive income after taxes	6.867.777,52	6.881.044,67	5.953.402,69	6.268.074,72	
	137.233.627,95	127.099.066,47	168.833.903,74	159.104.047,46	
Increase/decrease of parent company's share capital	0,00	0,00	0,00	0,00	
Dividends distributed	0,00	0,00	0,00	0,00	
Net income/(expense) recognised directly in equity Minority participation on subsidiaries' share capital	0,00	0,00	0,00	0,00	
increase/decrease	1.772.676,50	230.562,82	0,00	0,00	
Net equity of period Closing Balance (31/03/2009 and 31/03/2008 respectively)	139.006.304,45	127.329.629,29	168.833.903,74	159.104.047,47	

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 7 of 57

NOTES TO THE INTERIM FINANCIAL STATEMENTS OF THE PERIOD ENDED AT 31/03/2009

1. General information

The company "IASO" PRIVATE GENERAL, OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC – THERAPEUTIC & RESEARCH CENTER S.A. ("the Company") and its subsidiaries

- 1. IASO GENERAL CLINIC OF HOLARGOS S.A.
- 2. IASO MACEDONIAS GROUP OF NORTHERN GREECE S.A.
- 3. IASO OF SOUTHERN SUBURBS GENERAL CLINIC PRIVATE OBSTETRICS S.A.
- 4. MODERN MULTIFUNCTIONAL REHABILITATION-RESTORATION CENTER S.A.
- 5. IASO HEALTH ENTERPRISES S.A.
- 6. MEDSTEM HEALTH SUPPORT SERVICES S.A.
- 7. IASO THESSALIAS GENERAL CLINIC PRIVATE OBSTETRICS S.A.

(hereunder the Group) are engaged in providing health services.

The company "IASO" PRIVATE GENERAL, OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC – THERAPEUTIC & RESEARCH CENTER S.A., is a Société Anonyme (S.A.) and is listed on the Athens Stock Exchange. The address of its registered office is in Maroussi, 37 – 39, Kifisias Avenue, and its website address is www.iaso.gr.

The Interim Financial Statements of 31/03/2009 have been approved by the Board of Directors on 27/05/2009.

2. Summary of significant accounting policies

2.1 Basis of preparation of the financial statements

The accounting policies and methods of calculation applied for the interim financial statements are the same to those applied for the preparation of the audited annual financial statements for the previous fiscal years.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 8 of 57

In the year 2003 and 2004 the International Accounting Standards Board (IASB) issued a series of new International Financial Reporting Standards (IFRS) and revised the International Accounting Standards (IAS), which in combination with the existing unrevised standards issued by the International Accounting Standards Committee (IASC – International Accounting Standards Board IASB), are referred to as "The IFRS Stable

The Group adopts "The IFRS Stable Platform 2005" from 1 January 2005.

Adoption of IAS No. 1 (Revised 2003)

Platform 2005".

The application of the IAS 1 (revised 2003) lead to the reform of the presentation of the financial statements. The minority interests are presented henceforth in a separate row in the items of the Net Equity. Profit and loss attributable to the minority shareholders and those attributable to the Company's equity holders are presented henceforth as allocation of the net result for the period.

The preparation of financial statements in conformity with IFRS requires the use of certain critical accounting estimates and exercise of judgement in the process of applying the following accounting policies.

The financial statements of the parent company and its subsidiaries have been prepared under the historical cost convention, besides land and buildings, which have been measured at fair value and are analytically described below.

New accounting standards, amendments to existing standards and interpretations

Specific new standards, amendments of standards and interpretations have been published, which are mandatory for accounting periods beginning during the present year or later periods. The Company's (or Group's) assessment of the impact of these new standards and interpretations is set out below.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 9 of 57

I. Standards mandatory after the fiscal year 2008

IAS 39 (Amendment) "Financial Instruments: Recognition and Measurement" and IFRS 7 (Amendment) "Financial Instruments - Disclosures" - Reclassification of Financial Assets (applicable on or after 1 July 2008)

The amendment permits an entity to reclassify non-derivative financial assets (other than those designated at fair value through profit or loss by the entity upon initial recognition) out of the "fair value through profit or loss" category in particular circumstances. The amendment also permits an entity to transfer from the "available-for-sale" category to the "Loans and Receivables" category a financial asset that would have met the definition of "Loans and Receivables" (if the financial asset had not been designated as "available-for-sale"), if the entity has the intention and ability to hold that financial asset for the foreseeable future. This amendment has no impact on the financial statements of the Company and the Group.

IFRIC 11 - IFRS 2: "Group and Treasury Share Transactions" (applicable for annual periods beginning on or after 1 March 2007)

The interpretation clarifies the accounting for subsidiaries when they grant to employee equity instruments of the parent company. It also establishes as to whether the share-based payment transactions should be accounted for as cash-settled or equity-settled transactions. This interpretation has no impact on the financial statements of the Group and the Company.

IFRIC 14 – "The Limit on a Defined Benefit Asset, Minimum Funding Requirements and their Interaction" (applicable for annual periods beginning on or after 1 January 2008)

Interpretation 14 applies to all post-employment defined benefits and other long-term employee defined benefits. The interpretation clarifies when economic benefits in the form of refunds from the plan or reductions in future contributions to the plan should be regarded as available, how a minimum funding requirement might affect the economic benefit available in the form of reduction in future contributions and when a minimum funding requirement might give rise to a liability. The Company does not have such employee

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 10 of 57

benefit plans, and therefore this interpretation is not relevant for the Company's and the Group's operations.

II. Standards mandatory applicable after January 1st 2009

IAS 1 (Revised) "Presentation of Financial Statements" (applicable for annual periods beginning on or after 1 January 2009)

IAS 1 has been revised in order to upgrade the utility of the information presented in the financial statements. The main changes are: the statement of changes in equity shall present only transactions with owners of the parent, the introduction of a new statement of "comprehensive income", that aggregates all the items of income and expenses recognised in the income statement with the "other comprehensive income" and "restatements" in the financial statements or retrospective application of new accounting policies shall be presented from the beginning of the earlier comparative period. The Company and the Group apply the above amendments and make the necessary changes in the presentation of its financial statements for the year 2009.

IAS 23 (Amendment) "Borrowing Costs" (applicable for annual periods beginning on or after 1 January 2009)

This Standard supersedes the previous version of IAS 23. The substantial difference with respect to the previous standard relates to removing the option of immediately expensing the borrowing costs directly attributable to the acquisition of qualifying assets that necessarily take a substantial period of time to get ready for their intended use or sale. Such borrowing costs shall now be capitalized as part of the cost of that asset. Amendments also to IFRS 1, IAS 1, IAS 7, IAS 11, IAS 16, IAS 38 and IFRIC 1 were made and are applicable on or after 1 January 2009. The Company and the Group apply IAS 23 from 1 January 2009.

IAS 32 (Amendment) "Financial Instruments: Presentation" and IAS 1 (Amendment) "Presentation of Financial Statements" – Financial Instruments available by the holder (or "puttable instrument") (effective for annual periods beginning on or after 1 January 2009)

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 11 of 57

The amendment to IAS 32 requires some financial instruments available by the holder ("puttable") and obligations arising on liquidation to be classified as equity if specified criteria are met. The amendment to IAS 1 requires disclosure of specified information about the "puttable" instruments classified as equity, since the Company and the Group do not hold such instruments these amendments have no impact on the financial statements for the year 2009.

IFRS 1 (Amendment) "First-time Adoption of I.F.R.S" and IAS 27 (Amendment) "Consolidated and Separate Financial Statements" (applicable for annual periods beginning on or after 1 January 2009)

The amendment to IFRS 1 permits entities when adopting IFRSs for the first time to use as deemed cost either the fair value or the carrying amounts reported under previous GAAP for the measurement of the initial cost of an investment in a subsidiary, jointly controlled entity and associate. Also, the amendment abolishes the cost method defined by IAS 27 and replaces it by requiring dividends to be presented as income in the investor's separate financial statements. Amendments also to IAS 18, IAS 21 and IAS 36 were made and are applicable for periods beginning on or after 1 January 2009. Since the parent company and its subsidiaries have already adopted the IFRS this amendment has no impact on the financial statements for the year 2009.

IFRS 2 (Amendment) "Share-based Payment" – Non – vesting conditions (applicable for annual periods beginning on or after 1 January 2009)

The amendment clarifies the definition "vesting conditions" introducing the term "non-vesting conditions" for terms that do not relate to length of service or achievement of performance. It also clarifies that for all cancellations deriving either from the entity or the contracting parties shall be applied the same accounting treatment.

This amendment has no impact on the financial statements of the Company and the Group for the year 2009.

IFRS 8 – "Operating Segments" (applicable for annual periods beginning on or after 1 January 2009)

This standard replaces IAS 14 under which segments were recognised and reported on the basis of an analysis of risks and returns. According to IFRS 8 operating segments are

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

. Page 12 of 57

components of an entity about which separate financial information is available that is evaluated regularly by the Managing Director/Chief Operating Decision Maker and presented in the financial statements on the same basis as that used for internal reporting purposes. The Company and the Group apply IFRS 8 from 1 January 2009.

IFRIC 13 "Customer Loyalty Programmes" (applicable for annual periods beginning on or after 1 July 2008)

Interpretation 13 clarifies the accounting for companies granting some kind of customer loyalty incentive such as "loyalty points" or "free travelling miles" to customers buying goods or services. This interpretation is not relevant for the Company's and the Group's operations.

III. Annual Improvements

The following amendments describe the most significant changes entailed to IFRS as a result of the annual improvements plan of IASB published in May 2008. The following amendments unless otherwise indicated are applicable for annual periods beginning on or after 1 January 2009.

IAS 1 (Amendment) "Presentation of Financial Statements"

The amendment clarifies that some of the financial assets and financial liabilities that have been classified as held for trading in accordance with IAS 39 "Financial Instruments: Recognition and Measurement" constitute examples of current assets and current liabilities respectively. The Company and the Group apply this amendment from 1 January 2009, however, it has no impact on the financial statements.

IAS 16 (Amendment) "Property, Plant and Equipment" (and successive amendment to IAS 7 Statement of Cash Flows")

This amendment requires an entity that, in the course of its ordinary activities, routinely sells items of property, plant and equipment that it has held for rental to others shall transfer such assets to inventories at their carrying amount when they cease to be rented and become held for sale. The proceeds from the sale of such assets shall be recognised as revenue. The successive amendment to IAS 7 states that the cash flows generated from the

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 13 of 57

purchase, rental and sale of such assets are classified as cash flows from operating activities. This amendment has no impact on the Company's and the Group's operations, since it is not included in the course of its ordinary activities the rental and subsequent sale of assets. The Company and the Group apply these amendments from 1 January 2009, however they have no impact on the financial statements.

IAS 19 (Amendment) "Employee Benefits"

The changes in this standard are the following:

- a) A plan amendment resulting in a change in the extent to which the commitments for benefits are affected by future salary increases is a curtailment, while an amendment that changes the benefits attributable to past service causes a negative past service cost if it results in decrease of the present value of the defined benefit obligation.
- b) The definition of the return on plan assets has been amended in order to define that the costs of administering the plan are deducted at the return on plan assets calculation only in the extent that these costs were not included in the actuarial assumptions used to measure the defined benefit obligation.
- c) The distinction between Short-term and Long-term employee benefits shall rely on whether the employee benefits shall be settled within 12 months or beyond 12 months after the end of the period in which the employees render the related service.
- d) IAS 37 "Provisions, Contingent Liabilities and Contingent Assets" requires the contingent liabilities to be disclosed but not to be recognised. IAS 19 has been amended in order to be consistent.

The Company and the Group apply the amendments from 1 January 2009, however they have no impact on the financial statements.

IAS 20 (Amendment) "Accounting for Government Grants and Disclosures of Government Assistance"

This amendment requires the benefit of a government loan at a below-market rate of interest to be measured as the difference between the initial carrying value of the loan determined in accordance with IAS 39 "Financial Instruments: Recognition and Measurement" and the proceeds received. The benefit is accounted for in accordance with IAS 20. This amendment has no impact on the Company's and the Group's operations, since no government loans have been raised.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

. Page 14 of 57

IAS 23 Borrowing Cost (as revised in 2007) (Amendment)

By the amendment:

- (a) It is clarified that the interest expense should be calculated using the effective interest rate as described in IAS 39 Financial Instruments: Recognition and Measurement.
- (b) It is removed the possibility the borrowing costs to include amortisation of difference between par value of loan at receipt or repayment and amortisation of incidental costs relating to the loan arrangements.

The Company and the Group apply IAS 23 from 1 January 2009.

IAS 27 (Amendment) "Consolidated and Separate Financial Statements"

The amendment clarifies that in circumstances when investments in subsidiaries, which are accounted for in accordance with IAS 39 "Financial Instruments: Recognition and Measurement" have been classified as assets held for sale in accordance with IFRS 5 "Non-current Assets Held for Sale and Discontinued Operations" shall continue to be applied the IAS 39. This amendment has no impact on the financial statements of the Company and the Group, since it is the Company's policy the investments in subsidiaries to be recognised at cost in the separate financial statements.

IAS 28 (Amendment) "Investments in Associates" (and successive amendments to IAS 32 "Financial Instruments: Disclosure and Presentation" and to IFRS 7 "Financial Instruments: Disclosures")

According to this amendment, an investment in an associate is accounted for as a single asset for impairment testing and the amount of any impairment loss is not allocated to specified assets that form part of the carrying amount of the investment in the associate. Accordingly, any reversal of that impairment loss is recognised to the extent that the recoverable amount of the investment subsequently increases. The Company apply this amendment from 1 January 2009.

IAS 29 (Amendment) "Financial Reporting in Hyperinflationary Economies"

The guidance in this standard has been amended so as to present the fact that some assets and liabilities are measured at fair value instead of being carried at historical cost. This amendment has no impact on the Group's operations, since none of its subsidiaries operates in hyperinflationary economies.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 15 of 57

IAS 31 (Amendment) "Interests in Joint Ventures" (and successive amendments to IAS 32 "Financial Instruments: Disclosure and Presentation" and to IFRS 7 "Financial Instruments: Disclosures")

This amendment indicates that in circumstances when an investment in a joint venture is accounted for in accordance with IAS 39 "Financial Instruments: Recognition and Measurement" in addition to the required disclosures of IAS 32 "Financial Instruments: Disclosure and Presentation" and IFRS 7 "Financial Instruments: Disclosures") shall be made specified and not all the required disclosures of IAS 31 "Interests in Joint Ventures". The amendment has no impact on the Company's and the Group's operations, since they do not have interests in joint ventures that are accounted for in accordance with IAS 39.

IAS 36 (Amendment) "Impairment of Assets"

This amendment requires that in circumstances when the fair value less costs to sell is determined using discounted cash flow projections shall be made disclosures equivalent to those for the determination of the value due to use. The Company and the Group apply this amendment and will provide the required disclosure where applicable for the impairment tests from 1 January 2009.

IAS 38 (Amendment) "Intangible Assets"

This amendment indicates that a payment can be recognised as prepayment only if it has been made in advance of obtaining a right to access the goods or receiving the services. This amendment practically means that when the Company obtains a right to access goods or receive services then the payment should be recognised as expenditure. The Company and the Group apply the amendment from 1 January 2009.

IAS 38 (Amendment) "Intangible Assets"

This amendment deletes the expression indicating that there will exist "rare, if ever exists" evidence for the use of a method that results in a lower amortisation rate than that of the straight-line amortisation method. The amendment will not have at present any impact on the Company's and the Group's operations since all the intangible assets are amortised using the straight-line method.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 16 of 57

IAS 39 (Amendment) "Financial Instruments: Recognition and Measurement"

The changes in this standard are the following:

- a) It is possible to have transfers to and from the class of fair value through profit or loss when a derivative is qualified or derecognised as cash flow hedging instrument or as net investment hedging.
- b) The definition of financial asset or financial liability at fair value through profit or loss as regard to assets held for trading has been amended. It is clarified that a financial asset or a financial liability that is part of a portfolio of identified financial instruments that are managed together and for which there is evidence of a recent actual pattern of short-term profit-taking, is included in such a portfolio on initial recognition.
- The applicable guidance for designation and documentation of the hedging relationship for hedge accounting purposes indicates that a hedging instrument shall involve a party external to the reporting entity and reports one segment as example of an entity. This means that in order to be applied the hedge accounting at segment level, the requirements for hedge accounting shall be met at the same time by the segment that applies it. The amendment eliminates this requirement so as the IAS 39 to co-exist with the IFRS 8 "Operating segments" which requires the disclosure about reportable segments to rely on the information provided to the Managing Director/Chief Operating Decision Maker.
- d) When it is re-measured the carrying amount of a debit hedged item and discontinued the hedge accounting of fair value, the amendment clarifies that shall be used a revised effective interest rate (calculated on the date the hedge accounting of fair value was discontinued).

The Company and the Group apply IAS 39 (Amendment) from 1 January 2009. It has no impact on the financial statements of the Company.

IAS 40 (Amendment) "Investment Property" (and successive amendments to IAS 16 "Property, Plant and Equipment")

The amendment defines that property that is being constructed or developed for future use as investment property is inside the scope of this Standard. Therefore, when the fair value model is applied these items of investment property are measured at fair value. Instead, in cases where the fair value of investment property under construction cannot be measured reliably, this investment property is measured at cost till the most recent date when

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

. Page 17 of 57

construction is completed and when the fair value becomes reliably determinable. This amendment has no impact on the Company's and the Group's operations, since they do not own investment property under construction.

IAS 41 (Amendment) "Agriculture"

The amendment requires the use of a market discount rate when discounted cash flows is the basis for determining the fair value and abolishes the prohibition to be taken into account the biological transformation in determining the fair value. The amendment has no impact on the Company's and the Group's operations since they have not undertaken any agriculture-related activity.

IFRS 5 (Amendment) "Non – Current Assets Held for Sale and Discontinued Operations" (and successive amendments to IFRS 1 "First – time Adoption of International Financial Reporting Standards") (effective for annual periods beginning on or after 1 July 2009)

The amendment clarifies that all assets and liabilities of a subsidiary are classified as held for sale if a sale plan for partial disposal involves loss of control of a subsidiary and there should be made the related disclosures regarding this subsidiary when it is met the definition of a discontinued operation. The successive amendment to IFRS 1 indicates that these amendments shall be applied prospectively from the date of transition to IFRS. The Group does not hold non-current assets held for sale.

The following amendments will have no impact on the financial statements of the Company and the Group.

- IAS 8 Changes in accounting policies and fundamental Errors.
- IAS 10 Events occurring after the Balance Sheet date.
- IAS 20 Accounting for Government Grants and Disclosures of Government Assistance.
- IAS 29 Financial Reporting in Hyperinflationary Economies.
- IAS 34 Interim Financial Reporting.
- IAS 40 Investment Property.
- IAS 41 Agriculture (and successive amendments to IFRS 5 Non-Current assets held for sale and Discontinued operations, IAS 2 Inventories, IAS 36 Impairment of non-financial assets.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 18 of 57

2.2 Consolidation

Subsidiaries

An audit is achieved over which the Company has the power to govern the financial and operating policies of another entity with the intention of gain from its activities. The consolidated financial statements comprise the financial statements of the company as well as the entities audited by the company (its subsidiaries) at the end of the relevant fiscal year. The financial statements of the subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group. Inter-company transactions, balances, income and expenses are eliminated at consolidation.

2.3 Segment reporting

A business segment is a group of assets and operations engaged in providing products and services that are subject to risks and returns that are different from those of other business segments. The Group of companies IASO provides mainly health services, which comprise of hospital, diagnostic, therapeutic and research activities.

2.4 Foreign currency conversion

Functional and presentation currency

Items included in the financial statements of the Group's companies, are presented in their financial environment's currency, where every company operates (official currency). The consolidated financial statements are presented in euro, which is the official currency adopted by the Group's companies.

2.5 Property, plant and equipment

Property, plant and equipment, excluding the productive property, are shown at cost less the accumulated depreciation and impairment losses. Cost includes all directly attributable expenditure for the acquisition of the items.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 19 of 57

repairs and maintenance are charged to the income statement during the financial period in which they are incurred.

Productive property is shown at fair value, based on valuations by independent evaluators, less subsequent accumulative depreciation and impairment losses. The property is revaluated at regular time intervals so that the carrying amounts do not differ from the fair values at the balance sheet closing dates.

On each balance sheet date, the Group reviews the carrying amounts of tangible and intangible assets to determine whether there is any indication that such assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to assess the recoverable value of a specific asset, the Group estimates the recoverable value of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and respective value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is immediately recognized in the income statement, unless the relative asset is been readjusted, in which case, the impairment loss is handled as a reduction to the amount of readjustment.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised as income immediately, unless the relative asset is been readjusted, in which case, the reversal of the impairment loss is handled as an increase to the amount of readjustment.

When assets are sold, the adjustments between the value received and their book value is recorded as gains or losses in the income statement. For the operating assets estimated in fair values, the current revaluation reserve included in equity during the sale, is transferred retained earnings. The assets' residual values and useful lives are reviewed if appropriate,

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

. Page 20 of 57

at the Management's judgement. In case assets' book values overrun the recoverable amount of the assets, the adjustments (impairment) are recorded as expenses in the income statement. Land is not depreciated. Depreciation on other assets is calculated using the straight-line method to allocate their cost or revaluated amounts to their residual values over their estimated useful lives, as follows:

PROPERTY, PLANT AND EQUIPMENT	YEARS
Buildings (Main building of Maternity Clinic)	50
Machinery	5-30
Wireless communication network	30
High-tech machinery	5
Medium technology machinery	14
Special machinery	20
Vehicles	5-7
Passenger vehicles & motorcycles	5
Lorries	7
Other equipment	3-20
Furniture	20
Utensils	15
Office machines	10
Computers & electronic complexes	5
Telecommunication equipment	3

The productive property or those assets that their use has not yet been determined and are still at construction stage, are shown at cost less any impairment losses. The cost includes professional fees and borrowing costs. The depreciation of this property as well as of the Group's commences when the property is ready for use.

2.6 Intangible assets

Trademarks and licenses

Trademarks and licenses are carried at cost less accumulated amortization. Amortization is calculated using the straight-line method over their estimated, useful lives as follows:

Production and exploitation licences

Licence for exploitation of IASO General Clinic 50 years

Purchase of IASO trademark 20 years

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 21 of 57

<u>Computer software – other intangible assets</u>

Acquired computer software licenses are measured at acquisition cost less amortization. The amortization is carried out on a straight-line basis over their estimated useful lives which is as follows:

SAP R3 (the basic business computer software)

LIS (Central laboratory programme)

S years

RIS (Radiology software support)

ASTRAIA (Embryonic software support)

MUSE, QA (Cardiology department)

S years

MS OFFICE, WINDOWS 2000,XP,MS,MONEY

3 years

Costs associated with developing and maintaining computer software programmes are recognised as an expense to the fiscal year they incurred.

2.7 Construction contracts

The construction projects of the Group are auctioned, and then having carried out negotiations with the tenderers, the one with the lowest price wins the contract. The contracts prior to their signing are examined by the Legal, the Finance and the New Projects Department, then they are approved by the Board of Directors and are signed by the authorized members. The supervision and audit of the contracts' completion is done by the Finance and New Projects Departments.

2.8 Investments

Available-for-sale financial assets

Available-for-sale financial assets are non-derivatives. In particular it concerns Mutual fund Units "MIDCAP PRIVATE SECTOR 50" -EUROBANK and "shares of unlisted Companies". The fair values of shares listed in Official Capital Markets are based on current bid prices at balance sheet closing dates. If the market for a financial asset is not active, the Group establishes fair value by using valuation techniques, at balance sheet closing dates.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

. Page 22 of 57

2.9 Inventories

The inventories are reported at the lower value between the cost and the net realisable value. Cost is determined using the weighted average cost formula. Net realisable value is the estimated selling price of the inventories in the ordinary course of business of the Group companies decreased by the cost of sale and the distribution expenses. A provision for impairment of trade receivables is established when there is objective evidence that the Group will not be able to collect all of the amounts due according to the original terms of receivables. The amount of the provision is recognized in other expenses in the income statement.

2.10 <u>Trade receivables</u>

Trade receivables are recognised at their actual value less impairment losses (loss from doubtful receivables). The amount of the provision is recognised in the income statement.

2.11 Cash and cash equivalents

Cash and cash equivalents include cash in hand, sight deposits and time deposits of low risk.

2.12 Share capital

Ordinary shares are classified as equity. Share capital represents the value of company's shares in issue. Any excess of the fair value of the consideration received over the par value of the shares issued is recognized as "share premium" in shareholders equity.

Incremental costs directly attributable to the issue of new shares or options are shown in equity as a deduction, net of tax, from the proceeds. Expenses related to the issue of shares for acquisition of enterprises are included in cost of the enterprise that is acquired.

Where any Group company purchases the Company's equity share capital (treasury shares), the consideration paid, including any directly attributable incremental costs, is deducted from equity attributable to the Company's equity holders until the shares are cancelled,

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 23 of 57

reissued or disposed off. Every gain or loss from sale of treasury shares net of other direct transaction expenses & taxes, if applicable, is shown as a reserve in equity.

2.13 Borrowings

Borrowings are recognised at their value, reduced by any transaction costs. The fair value of the liability portion of a convertible bond is determined using a market interest rate for an equivalent non-convertible bond. This amount is recorded as a liability on an amortised cost basis until extinguished on conversion or maturity of the bonds.

2.14 <u>Deferred income tax</u>

Current income tax is calculated using the financial statements of every company included in the consolidated financial statements, along with the applicable tax law. The income tax charge consists of the current income tax calculated upon the results of the Group companies, as they have been reformed in their taxation return applying the applicable tax rate.

Deferred income tax is determined using the liability method, on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts.

Deferred income taxation is determined using tax rates that have been enacted on the balance sheet date and are expected to apply when the related deferred income tax asset is realised or the related deferred income tax liability is settled. Deferred tax is charged or credited in the income statement, except when it relates to items credited or charged directly to equity, in which case the deferred tax is also presented in equity.

Deferred income tax assets are recognised to the extent that is probable that future taxable profit will be available against which the temporary differences can be utilised.

2.15 Employee benefits

Short-term benefits

Short-term employee benefits towards the employees in money and in kind are recognised as an expense when accrued.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 24 of 57

Pension obligations

The liability recorded in the balance sheet in respect of defined benefit pension plans is the present value of the defined benefit obligation for the defined benefit less the fair value of the assets of the plan and the changes occurring from other actuarial gains or losses and past service costs. The defined benefit obligation is calculated annually using the projected unit credit method. The present value of the defined benefit obligation is determined by discounting the estimated future cash outflows using interest rates of high-quality corporate bonds that are denominated, in the currency in which the benefits will be paid, and that have terms to maturity approximating to the terms of he related pension liability.

Past-service costs are recognised immediately in income, unless the changes to the pension plan are conditional on the employees remaining in service for a specified period of time (the vesting period). In this case, the past-service costs are amortised on a straight-line basis over the vesting period. Termination benefits are payable when employment is terminated before the normal retirement date. The Group recognises termination benefits when it is demonstrably committed. Benefits following due more than 12 months after the balance sheet date are discounted to present value.

2.16 Provisions

Provisions are recognised when the Group has a present legal or constructive obligation as a result of past events, it is more likely than not that be required to settle the obligation.

2.17 Revenue recognition

Revenue is measured at fair value of the sale of goods and services, net of value-added tax, rebates and discounts and after eliminating sales within the Group. Revenue is recognised as follows:

Sales of services

Sales of services are recognised in the accounting period (invoices & with provision) in which the services are rendered.

Page 25 of 57

Sales of goods

Sales of goods are recognised when a Group entity has delivered products to the customer; the customer has accepted the products and the collection of the related receivables is reasonably assured.

Interest income

Interest income is recognised on a time-proportion basis using the effective interest method.

Dividend income

Dividend income is recognised when the right to receive payment is established.

Income from rents

Income from rents is recorded when accrued, according to the existing contracts.

2.18 <u>Leases</u>

Leases where the lessor retains substantially all the risks and rewards of ownership are classified as operating leases.

Lessor

Rental income is recognised on a straight-line basis over the lease term.

Lessee

Payments made under operating leases are charged to the income statement on a straightline basis over the period of the lease.

2.19 <u>Dividend Distribution</u>

Dividend distribution is recognised as a liability in the fiscal period's financial statements in which the management's dividend policy is approved by the Ordinary Company's Shareholders Meeting.

2.20 Government grants

Government grants for training staff after they are certified and settled by the competent Government body (Ministry of Labour – OAED [Manpower, Employment Organisation]) are recognised in income (provision). Government grants received in respect of expenses are reflected in the income statement when the related expense is incurred so that the expense is matched to the income received. Government grants relating to assets are

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

. Page 26 of 57

recognised in liabilities (current or non-current) as grants for PPE and are credited to the income statement according to the respective assets useful life.

3. Financial risk management

3.1 Fair value estimation

The fair value of financial instruments traded in active capital markets (stock exchange) is based on quoted market prices at the annual balance sheet or the balance sheet of the period. The fair value of financial instruments that are not traded in an active market is determined at historical cost (acquisition cost) at the balance sheet date. The nominal value less estimated credit adjustment of trade receivables and payables are assumed to approximate their fair values.

3.2 Financial Risk

Financial risk management performs a very significant role within the group's total risk management policy. The Group's financial instruments consist mainly of deposits with banks, trade accounts receivable and payable, transactions with the subsidiaries, associates, equity investments, dividends payable and lease obligations. The interest rate risk exposure for bank liabilities and investments is continuously audited in budgetary base. Regarding the proper management of the liquidity, this is done by combination of working capital and cash flows, approved bank credit and strict monitoring of cash flows.

The Group has sufficient undrawn call/demand borrowing facilities that can be utilized to fund any potential shortfall in cash resources.

4. Critical accounting estimates and judgments

Estimates and judgements are continually evaluated and are based on historical experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 27 of 57

4.1 Critical accounting estimates and assumptions

The Group makes estimates and assumptions concerning the future. The estimates and assumptions that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below:

Income taxes

The Group is subject to uniform income tax rate given that all Group companies activate in Greece. Where the final tax outcome of these matters is different from the amounts that were initially recorded, such differences will impact the income tax and deferred tax provisions in the period in which such determination is made.

Litigious cases

The Group, conducts estimations regarding the pending lawsuits and proceeds to provisions when it is believed that the Company's and the Group's accounting balances of fixed assets and liabilities will be substantially affected. The estimations are important but not restrictive. The actual future events may differ than the above estimations.

Fair value and useful lives of Property, plant and equipment

In addition, management makes estimations in relation to useful lives of amortized assets. Further information is given in paragraph 2.5.

Estimated impairment of goodwill

Group's management examines annually whether goodwill has suffered any impairment, in accordance with the accounting policy stated in Note 2.5.

5. Information by Business Unit

Principal Information

The following information refers to the business units of the Group's companies, which should be reported individually in the financial statements.

The business units have been defined based on the Group's companies structure considering also the fact that the decision-makers monitor their financial information individually, as presented by the company for each of its subsidiaries included in the consolidation.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 28 of 57

Using the quantitative criteria set by the relevant IFR standard, IASO S.A. and its subsidiaries were set as business units that must be reported individually in the financial statements. The accounting principles are the same with the ones used at the Annual Financial Statements and consist of independent units – companies.

The Management evaluates the performance of these business units, based on the operating and the net profits, as well as the potential synergies between the business units and the complement of services in the whole spectrum of health services in the human life-cycle.

The parent company "IASO S.A" operates in the health care sector, covering all the obstetrics and gynecology cases and a broad range of diagnostic and therapeutic services. Its operations, in short, can be classified to inpatients cases (obstetrics and surgical) and outpatients cases (diagnostic laboratories and outpatients departments).

The subsidiary company "IASO GENERAL CLINIC OF HOLARGOS S.A." operates also in the health care sector, as a general hospital, covering all surgical and non-surgical cases with the exception of the obstetrics and gynecology related cases. It also operates complete and fully organized diagnostic laboratories, outpatient departments and emergency units. Its operation can be classified to inpatient cases (surgical, non-surgical) that require hospitalization and outpatients cases (diagnostic laboratories, outpatient departments, etc) that do not require patient hospitalization.

The subsidiary company "MEDSTEM SERVICES S.A." operates mainly in the healthcare supporting services, with its main objective, from 01/01/2006 being the processing and storage of infant stem cells. In addition to the aforementioned provision of health services, it also operates in parallel non-medical services that at the moment are not considered important due to their small contribution to the Group's total revenue. These services where necessary will be mentioned totally as "Other services provided".

The Group's other subsidiaries are either in a construction stage or have not commenced productive activity yet and lack any revenues. However, due to the reconciliation of operating and net profits in a consolidated base they will be presented individually by the title "Other companies".

Page 29 of 57

I. Total Comprehensive Income per Business Unit for the period 01/01-31/03/2009 and 01/01-31/03/2008 respectively, are analysed as follows:

01/01 - 31/03/2009	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
Inpatients revenues	20.700.674,74	16.612.361,89	0,00	0,00	37.313.036,63		37.313.036,63
Inpatients number of cases	7.136	4.103					
Outpatients revenues	6.034.692,49	1.743.704,19	696.078,85	0,00	8.474.475,53		8.474.475,53
Outpatients number of cases	58.440	15.766					
Other revenues	5.099,65	2.313,70	0,00	0,00	7.413,35		7.413,35
Other services provided	0,00	0,00	308.310,11	0,00	308.310,11		308.310,11
Revenues from Group's customers	26.740.466,88	18.358.379,78	1.004.388,96	0,00	46.103.235,62		46.103.235,62
Inter-company sales	32.497,96	39.483,64	0,00	0,00	71.981,60	-71.981,60	0,00
Other operating revenues. expenses	994.702,35	164.852,57	2.100,57	0,00	1.161.655,49	-33.041,10	1.128.614,39
Operational expenses	-19.080.264,51	-17.310.838,74	-743.862,74	-57.106,49	-37.192.072,48	105.022,70	-37.087.049,78
Financial cost	-636.602,18	-310.010,90	770,79	75.569,86	-870.272,43		-870.272,43
Earnings before taxes	8.050.800,50	941.866,35	263.397,58	18.463,37	9.274.527,80		9.274.527,80
Income taxes	-2.097.397,81	-235.466,59	-65.849,40	-8.036,48	-2.406.750,27		-2.406.750,27
Net profit/loss for the period (A)	5.953.402,69	706.399,76	197.548,19	10.426,89	6.867.777,52		6.867.777,52
Other comprehensive income after taxes (B)	0,00	0,00	0,00	0,00	0,00		0,00
Total comprehensive income after taxes (A)+(B)	5.953.402,69	706.399,76	197.548,19	10.426,89	6.867.777,52		6.867.777,52

01/01 - 31/03/2008	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
Inpatients revenues	20.184.298,23	16.546.955,11	0,00	0,00	36.731.253,34		36.731.253,34
Inpatients number of cases	6.736	4.252					
Outpatients revenues	6.242.676,88	1.725.000,59	860.348,30	0,00	8.828.025,77		8.828.025,77
Outpatients number of cases	57.800	15.044					
Other revenues	6.191,71	356,26	0,00	0,00	6.547,97		6.547,97
Other services provided	0,00	0,00	257.691,58	0,00	257.691,58		257.691,58
Revenues from Group's customers	26.433.166,82	18.272.311,96	1.118.039,88	0,00	45.823.518,66		45.823.518,66
Inter-company sales	41.669,71	41.961,32	0,00	0,00	83.631,03	-83.631,03	0,00
Other operating revenues. expenses	462.590,43	-161.611,07	22,34	-787,90	300.213,80	-32.075,71	268.138,09
Operational expenses	-17.592.562,44	-16.910.140,70	-815.702,23	-53.146,04	-35.371.551,41	115.706,74	-35.255.844,67
Financial cost	-871.105,81	-696.399,80	16.729,62	46.015,88	-1.504.760,11		-1.504.760,11
Earnings before taxes	8.473.758,71	546.121,71	319.089,61	-7.918,06	9.331.051,97		9.331.051,97
Income taxes	-2.205.683,99	-136.530,43	-109.772,40	1.979,52	-2.450.007,30		-2.450.007,30
Net profit/loss for the period (A)	6.268.074,72	409.591,28	209.317,21	-5.938,54	6.881.044,67		6.881.044,67
Other comprehensive income after taxes (B)	0,00	0,00	0,00	0,00	0,00		0,00
Total comprehensive income after taxes (A)+(B)	6.268.074,72	409.591,28	209.317,21	-5.938,54	6.881.044,67		6.881.044,67

The statement of comprehensive income for the Company and the Group at 31/3/2009 and 31/3/2008 respectively, does not include income and expenses that are included in 'Other revenues' account as indicated by the revised IAS 1 or allowed by other IFRS .

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 30 of 57

II. Assets' and Liabilities' allocation per Business Unit at 01/01-31/03/2009 and 01/01-31/03/2008 respectively is analysed as follows:

01/01 - 31/03/2009	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
Assets per Business Unit							
Operating assets per B. U.	141.694.398,15	100.286.647,14	2.185.501,87	0,00	244.166.547,16	0,00	244.166.547,16
Non allocated assets per B.U.	143.251.949,31	10.172.298,47	5.006.588,59	86.248.474,65	244.679.311,02	-134.533.443,11	110.145.867,91
Total	284.946.347,46	110.458.945,61	7.192.090,46	86.248.474,65	488.845.858,18	-134.533.443,11	354.312.415,07
Liabilities per Business Unit							
Operating assets per B. U.	21.969.196,50	68.264.156,41	5.271.398,61	0,00	95.504.751,52	0,00	95.504.751,52
Non allocated assets per B.U.	94.143.247,22	9.640,88	365.982,53	29.045.365,72	123.564.236,35	-3.762.877,25	119.801.359,10
Total	116.112.443,72	68.273.797,29	5.637.381,14	29.045.365,72	219.068.987,87	-3.762.877,25	215.306.110,62

01/01 – 31/03/2008 Assets per Business Unit	IASO S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Other Companies	TOTAL	Intra-group eliminations	GROUP
Operating assets per B. U.	120.471.739,44	94.312.289,66	2.066.869,13	0,00	216.850.898,23	0,00	216.850.898,23
Non allocated assets per B.U.	130.236.562,26	18.704.361,99	4.056.760,30	62.180.467,55	215.178.152,10	-113.508.692,85	101.669.459,25
Total	250.708.301,70	113.016.651,65	6.123.629,43	62.180.467,55	432.029.050,33	-113.508.692,85	318.520.357,48
Liabilities per Business Unit							
Operating assets per B. U.	20.042.103,86	97.268.461,10	3.834.665,96	0,00	121.145.230,92	0,00	121.145.230,92
Non allocated assets per B.U.	71.562.150,38	9.279,00	436.760,08	9.401.132,98	81.409.322,44	-11.363.825,17	70.045.497,27
Total	91.604.254,24	97.277.740,10	4.271.426,04	9.401.132,98	202.554.553,36	-11.363.825,17	191.190.728,19

Page 31 of 57

6. Property, plant and equipment

Property, plant and equipment of the Company at 31.03.2009

			Other property,	
	Land & Buildings	Vehicles & Machinery	plant & equipment	Total
01.01.2009				
Cost or valuation	116.142.040,71	37.421.957,57	10.923.829,10	164.487.827,38
Accumulated depreciation	9.805.617,27	17.482.783,52	7.668.882,50	34.957.283,29
Net book amount	106.336.423,44	19.939.174,05	3.254.946,60	129.530.544,09
Movement 01.01 - 31.03.2009			_	
Opening net book amount	106.336.423,44	19.939.174,05	3.254.946,60	129.530.544,09
Revaluation surplus	0,00	0,00	0,00	0,00
Additions	1.031.568,23	458.376,76	49.618,88	1.539.563,87
Disposals	0,00	0,00	0,00	0,00
Depreciation charge	465.222,63	593.698,64	155.729,05	1.214.650,32
Net book amount	106.902.769,04	19.803.852,17	3.148.836,43	129.855.457,64
31.03.2009				
Cost or valuation	117.173.608,94	37.880.334,33	10.973.447,98	166.027.391,25
Accumulated depreciation	10.270.839,90	18.076.482,16	7.824.611,55	36.171.933,61
Net book amount	106.902.769,04	19.803.852,17	3.148.836,43	129.855.457,64

Property, plant and equipment of the Company at 31.03.2008

	Land &	Vehicles &	Other property, plant &	
	Buildings	Machinery	equipment	Total
01.01.2008				
Cost or valuation	79.450.797,41	27.023.038,61	37.002.216,19	143.476.052,21
Accumulated depreciation	8.321.069,50	15.664.957,21	7.061.748,68	31.047.775,39
Net book amount	71.129.727,91	11.358.081,40	29.940.467,51	112.428.276,82
Movement 01.01 - 31.03.2008				
Opening net book amount	71.129.727,91	11.358.081,40	29.940.467,51	112.428.276,82
Revaluation surplus	0,00	0,00	0,00	0,00
Additions	15.349,95	81.481,13	99.546,88	196.377,96
Disposals	0,00	10.913,31	387,85	11.301,16
Depreciation charge	345.466,66	411.046,42	139.050,20	895.563,28
Net book amount	70.799.611,20	11.017.602,80	29.900.576,34	111.717.790,34
31.03.2008				
Cost or valuation	79.466.147,36	27.093.606,43	37.101.375,22	143.661.129,01
Accumulated depreciation	8.666.536,16	16.076.003,63	7.200.798,88	31.943.338,67
Net book amount	70.799.611,20	11.017.602,80	29.900.576,34	111.717.790,34

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 32 of 57

Property, plant and equipment of the Group at 31.03.2009

	Land & Buildings	Vehicles & Machinery	Other property, plant & equipment	Total
01.01.2009				
Cost or valuation	234.958.829,12	63.635.947,06	24.878.461,74	323.473.237,92
Accumulated depreciation	15.054.335,80	31.243.720,25	15.184.805,47	61.482.861,52
Net book amount	219.904.493,32	32.392.226,81	9.693.656,27	261.990.376,40
Movement 01.01 - 31.03.2009				
Opening net book amount	219.904.493,32	32.392.226,81	9.693.656,27	261.990.376,40
Revaluation surplus	0,00	0,00	0,00	0,00
Additions	8.448.817,36	539.421,60	87.014,04	9.075.253,00
Disposals	0,00	28.839,32	20.066,53	48.905,85
Depreciation charge	659.889,13	1.134.315,01	291.848,89	2.086.053,03
Net book amount	227.693.421,55	31.768.494,08	9.468.754,89	268.930.670,52
31.03.2009				
Cost or valuation	243.407.646,48	64.146.529,34	24.945.409,25	332.499.585,07
Accumulated depreciation	15.714.224,93	32.378.035,26	15.476.654,36	63.568.914,55
Net book amount	227.693.421,55	31.768.494,08	9.468.754,89	268.930.670,52

Property, plant and equipment of the Group at 31.03.2008

	Other property,			
	Land & Buildings	Vehicles & Machinery	plant & equipment	Total
01.01.2008				
Cost or valuation	160.203.288,19	53.155.929,36	58.141.044,24	271.500.261,79
Accumulated depreciation	12.842.075,63	27.394.115,88	13.947.859,90	54.184.051,41
Net book amount	147.361.212,56	25.761.813,48	44.193.184,34	217.316.210,38
Movement 01.01 - 31.03.2008			·	
Opening net book amount	147.361.212,56	25.761.813,48	44.193.184,34	217.316.210,38
Revaluation surplus	0,00	0,00	0,00	0,00
Additions	4.938.378,12	260.021,99	118.187,63	5.316.587,74
Disposals	0,00	10.913,31	387,85	11.301,16
Depreciation charge	527.325,96	946.166,63	301.320,41	1.774.813,00
Net book amount	151.772.264,72	25.064.755,53	44.009.663,71	220.846.683,96
31.03.2008				
Cost or valuation	165.141.666,31	53.405.038,04	58.258.844,02	276.805.548,37
Accumulated depreciation	13.369.401,59	28.340.282,51	14.249.180,31	55.958.864,41
Net book amount	151.772.264,72	25.064.755,53	44.009.663,71	220.846.683,96

The Group's land and buildings were last revaluated at 31.12.2008 by independent certified evaluators. Valuations were made on the basis of open market value. The revaluation surplus of the Company and the Group amounted to € 9.926.808,77 and € 17.604.051,49

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 33 of 57

respectively, and was credited to other reserves in shareholders' equity (More details in Note 29).

On the assets of the Company and the Group there are no real liens, apart from the subsidiary IASO GENERAL CLINIC OF HOLARGOS S.A. where there is a prenotation against its fixed assets amounted to \in 54.000.000,00 in favor of the National Bank of Greece for securing debenture loan of \in 45.000.000,00, whose unpaid balance at 31/03/2009 amounted to \in 27.500.000,00.

The Parent company IASO S.A., invested the amount of approximately €1,54 mil., mainly as follows:

- The amount of € 1,03 mil. was invested in buildings, mainly for the completion of IASO Children's hospital, as well as for the restruction and expansion of existing operating units.
- The amount of €0,46 mil. was invested in biomedical equipment for the commencement of operation of IASO Children's hospital.

At IASO Thessalias S.A. the new investments amounted approximately to €7,3 mil., regarding the completion of the buildings construction, where the company's clinic will operate.

At IASO General S.A. were invested 0.19 mil. in biomedical equipment for the operation of existing units.

At the subsidiary **MEDSTEM Services S.A.**, were invested \in 0,04 mil.

The aforementioned **Group** investments reached the total amount of \in 9,07 mil. illustrating the Group's policy to create increased value for its shareholders by further development of the Group's competitive strengths and continuous upgrade of the offered services.

Page 34 of 57

7. Intangible assets

Intangible assets of the Company at 31.03.2009

	Trademarks & Licenses	Other	Total
1.1.2009			
Cost	139.286,87	2.404.909,32	2.544.196,19
Accumulated depreciation and			
impairment	28.841,35	1.502.685,39	1.531.526,74
Net book amount	110.445,52	902.223,93	1.012.669,45
Movement 01.01 - 31.03.2009			
Opening net book amount	110.445,52	902.223,93	1.012.669,45
Additions	0,00	10.710,00	10.710,00
Depreciation charge	712,84	46.028,09	46.740,93
Net book amount	109.732,68	866.905,84	976.638,52
31.03.2009			
Cost	139.286,87	2.415.619,32	2.554.906,19
Accumulated amortization and			
impairment	29.554.19	1.548.713,48	1.578.267,67
Net book amount	109.732,68	866.905,84	976.638,52

Intangible assets of the Company at 31.03.2008

	Trademarks & Licenses	Other	Total
1.1.2008			
Cost	139.286,87	2.052.349,54	2.191.636,41
Accumulated depreciation and impairment	25.990,01	1.282.032,41	1.308.022,42
Net book amount	113.296,86	770.317,13	883.613,99
Movement 01.01 - 31.03.2008			_
Opening net book amount	113.296,86	770.317,13	883.613,99
Additions	0,00	6.435,23	6.435,23
Depreciation charge	712,84	51.383,11	52.095,95
Net book amount	112.584,02	725.369,25	837.953,27
31.03.2008			
Cost	139.286,87	2.058.784,77	2.198.071,64
Accumulated amortization and			
impairment	26.702,85	1.333.415,52	1.360.118,37
Net book amount	112.584,02	725.369,25	837.953,27

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 35 of 57

Intangible assets of the Group at 31.03.2009

	Trademarks & Licenses	Other	Total
1.1.2009			
Cost	139.286,87	4.682.900,37	4.822.187,24
Accumulated depreciation and impairment	28.841,35	3.236.499,54	3.265.340,89
Net book amount	110.445,52	1.446.400,83	1.556.846,35
Movement 01.01 - 31.03.2009			
Opening net book amount	110.445,52	1.446.400,83	1.556.846,35
Additions	0,00	12.852,00	12.852,00
Depreciation charge	712,84	83.322,14	84.034,98
Net book amount	109.732,68	1.375.930,69	1.485.663,37
31.03.2009			
Cost	139.286,87	4.695.752,37	4.835.039,24
Accumulated amortization and impairment	29.554,19	3.319.821,68	3.349.375,87
Net book amount	109.732,68	1.375.930,69	1.485.663,37

Intangible assets of the Group at 31.03.2008

	Trademarks & Licenses	Other	Total
1.1.2008			
Cost Accumulated depreciation and	139.286,87	4.194.251,29	4.333.538,16
impairment	25.990,01	2.887.103,12	2.913.093,13
Net book amount	113.296,86	1.307.148,17	1.420.445,03
Movement 01.01 - 31.03.2008			
Opening net book amount	113.296,86	1.307.148,17	1.420.445,03
Additions	0,00	6.435,23	6.435,23
Depreciation charge	712,84	78.687,51	79.400,35
Net book amount	112.584,02	1.234.895,89	1.347.479,91
31.03.2008		_	
Cost Accumulated amortization and	139.286,87	4.200.686,52	4.339.973,39
impairment	26.702,85	2.965.790,63	2.992.493,48
Net book amount	112.584,02	1.234.895,89	1.347.479,91

Other intangible assets exclusively concern software applications of the Company like the accounting data management system, the personnel management system as well as the medical services costing management application. The estimated life cycle of the above intangible assets is demonstrated in chapter 2.6; they are amortised annually. The management re-exams their values at reasonable periods and any adjustments will respectively increase or decrease their present value.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 36 of 57

8. Transactions with related parties

The participations, inter-company transactions, balances and income and expenses are eliminated upon consolidation.

8.1 Inter-company transactions

Inter-company income and expenses of the Group's companies for the period 01/01-31/03/2009:

IASO S.A. SALES TO RELATED PARTIES						
	0:	1/01-31/03/2009		01/01-31/03/2009		
DESCRIPTION	IASO GENERAL	MEDSTEM	TOTAL	IASO GENERAL	MEDSTEM	TOTAL
Sales of Consumables	2.059,83	2.084,45	4.144,28	1.575,00	4.616,71	6.191,71
Sales of Fixed Assets	0,00	0,00	0,00	0,00	0,00	0,00
Other services	0,00	220,68	220,68	0,00	221,50	221,50
Revenues from services provision	28.133,00	0,00	28.133,00	35.478,00	0,00	35.478,00
Rents and tenancy joint expenses	0,00	33.041,10	33.041,10	0,00	31.854,21	31.854,21
TOTAL	30.192,83	35.346,23	65.539,06	37.053,00	36.692,42	73.745,42

IASO S.A. PURCHASES FROM RELATED PARTIES						
	01	1/01-31/03/2009		0	1/01-31/03/2009	
DESCRIPTION	IASO GENERAL	MEDSTEM	TOTAL	IASO GENERAL	MEDSTEM	TOTAL
Outsourced processed services	39.255,16	0,00	39.255,16	41.605,06	0,00	41.605,06
Medical supplies	228,48	0,00	228,48	356,26	0,00	356,26
Purchases of fixed assets	0,00	3.200,00	3.200,00	0,00	0,00	0,00
Consumables	0,00	0,00	0,00	0,00	0,00	0,00
TOTAL	39.483,64	3.200,00	42.683,64	41.961,32	0,00	41.961,32

FEES OF DIRECTORS AND MEMBERS OF THE B.O.D. BASED ON IAS 24						
	Group Company					
Directors' Fees (1)	264.415,31	264.415,31				
Members of BoD Fees (2)	54.812,00	54.075,00				
Total	319.227,31	318.490,31				

1. The Directors' fees include wages, employers' social security contributions, other fees, extraordinary fees, bonuses, firing compensations and other fringe benefits.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 37 of 57

2. There is no remuneration for the BoD Members regarding their capacity as Members of the BoD. The aforementioned fees refer exclusively to payments for the provision of health care services to the Company or the Group under the professional capacity as medical doctors as self-employed professionals.

In the Financial Statements, that are published according to the Hellenic Capital Market Committee's relevant decision as well as article 135 L.2190/1920, BoD's fees (case 2) have been included in "Purchases of Consumables and Services" of the additional data in the published Condensed Financial Data and Information of the Group and the Company.

RECEIVABLES AND LIABILITIES OF RELATED PARTIES AT 31/03/2009							
		RECEIVABLES					
LIABILITIES	IASO S.A.	MODERN MULTIFUNCTIONAL CENTER S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Total		
IASO S.A.	-	-	350,00	7.408,00	7.758,00		
MEDSTEM SERVICES S.A.	12.493,50	-	-	-	12.493,50		
IASO GENERAL S.A.	162.864,88	-	-	-	162.864,88		
TOTAL	175.358,38	-	350,00	7.408,00	183.116,38		

RECEIVABLES AND LIABILITIES OF RELATED PARTIES AT 31/03/2008							
		RECEIVABLES					
LIABILITIES	IASO S.A.	MODERN MULTIFUNCTIONAL CENTER S.A.	IASO GENERAL S.A.	MEDSTEM SERVICES S.A.	Total		
IASO S.A.	-	-	273.244,41	26.385,55	299.629,96		
MEDSTEM SERVICES S.A.	13.578,33	-	156,56	-	13.734,89		
IASO GENERAL S.A.	4.240.803,07	2.790.000,00	-	38.564,68	7.069.367,75		
TOTAL	4.254.381,40	2.790.000,00	273.400,97	64.950,23	7.382.732,60		

The inter-company and intra group income and expenses, the receivables and liabilities as well as the fees of Directors and the Members of the BoD consist transactions with related parties according to IAS 24.

8.2 Investments to subsidiaries

Parent Company's as well as subsidiaries' participations in other Group's non-listed companies were evaluated by the method of "acquisition value", which is the method that

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 38 of 57

will always be used by the Group. Subsidiaries' financial statements are prepared according to the Group's accounting principles. The initial goodwill (initial consolidation adjustment) has been reflected in the consolidated profit and loss statements.

INVESTMENTS TO SUBSIDIARIES AT 31/03/2009	% OF PARTICIPATION (Direct & Indirect)	PARENT COMPANY'S PARTICIPATION	EQUITY 31/03/2009	MINORITY INTERESTS
1. IASO GENERAL CLINIC OF HOLARGOS S.A.	97,07%	98.013.771,50	42.185.148,32	1.236.532,21
2. IASO MACEDONIAS HEALTH GROUP OF NORTHERN GREECE S.A.	100,00%	6.717.159,86	21.298.517,16	0,00
3. IASO OF SOUTHERN SUBURBS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.	53,43%	3.374.400,00	10.502.411,36	4.891.033,52
4. MODERN MULTIFUNCTIONAL REHABILITATION-RESTORATION CENTER S.A.	99,97%	4.861.890,00	5.045.241,57	1.468,87
5. IASO HEALTH ENTERPRISES S.A.	99,97%	297.000,00	318.763,11	95,63
6. MEDSTEM SERVICES S.A.	99,97%	475.200,00	1.554.709,32	457,27
7. IASO THESSALIAS GENERAL CLINIC- PRIVATE OBSTETRICS S.A.	71,20%	10.746.310,00	20.038.175,73	5.770.633,35
TOTAL		124.485.731,36	100.942.966,57	11.900.220,85

INVESTMENTS TO SUBSIDIARIES AT 31/12/2008	% OF PARTICIPATION (Direct & Indirect)	PARENT COMPANY'S PARTICIPATION	EQUITY 31/03/2008	MINORITY INTERESTS
1. IASO GENERAL CLINIC OF HOLARGOS S.A.	97,07%	98.013.771,50	41.478.748,56	1.215.826,21
2. IASO MACEDONIAS HEALTH GROUP OF				
NORTHERN GREECE S.A.	100,00%	6.717.159,86	21.301.611,11	0,00
3. IASO OF SOUTHERN SUBURBS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.	53,43%	3.374.400,00	10.452.854,27	4.867.954,50
4. MODERN MULTIFUNCTIONAL REHABILITATION-RESTORATION CENTER S.A.	99,97%	4.861.890,00	5.043.408,24	1.468,33
5. IASO HEALTH ENTERPRISES S.A.	99,97%	297.000,00	316.540,58	94,96
6. MEDSTEM SERVICES S.A.	99,97%	475.200,00	1.357.161,14	399,17
7. IASO THESSALIAS GENERAL CLINIC-				
PRIVATE OBSTETRICS S.A.	67,93%	8.246.309,00	11.578.265,85	3.713.238,15
TOTAL		121.985.730,36	91.528.589,75	9.798.981,32

In addition:

1) On 03/03/2009, the share capital increase, through cash payment with preemption rights in favor of the existing shareholders, of the subsidiary company "IASO THESSALIAS GENERAL CLINIC-PRIVATE OBSTETRICS S.A." was completed. The aforementioned share capital increase was decided on 01/11/2008 by the Extraordinary Shareholders Meeting of the company and took place from 01/11/2008 until 03/03/2009. It was covered

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 39 of 57

by 44,22% by the deposit of € 3.758.779,50, which corresponds to 1.073.937 new common registered shares with voting rights, while 1.354.635 shares were left indisposed.

Upon resolution of the Board of Directors dated 03/03/2009, the indisposed shares (1.354.635) were disposed by their judgment to new shareholders that were interested in participating and deposited the relevant amounts along with the existing shareholders that chose to participate beyond their preemption right and deposited the relevant amounts. As a result the total coverage of the share capital increase was 100% and amounted to 68.500.002,00. Following that, the share capital of the company will increase by 4.857.144,00 through the issuance of 2.428.572 new common registered shares with voting rights, of nominal value 2.00 per share. The par value of the shares issued, amounting 3.642.858, is recognized as "share premium" in shareholders equity.

- 2) Upon resolution, of IASO Thessalias Board of Directors, on 12/03/2009, it was decided to conduct an Extraordinary Shareholders Meeting on the 4rth of April 2009, at the company's registration address Kouma & 28th Oktovriou 14, (1st floor) for discussing the following agenda:
- Share capital increase by cash and public offer and issuance of new shares
- Amendment of article 3 of the company's articles of association due to the aforementioned share capital increase.
- 3) IASO S.A., on 19/03/2009, announced that its subsidiary company IASO of Southern Suburbs S.A. and the constructing company INTRAKAT S.A. signed a memorandum of cooperation for the construction of a clinic in the municipality of Agios Ioannis Redis. The budget of this project is € 70 mil.

9. Available-for-sale financial assets

Available-for-sale financial assets include the following:

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Listed securities:	None	None	None	None
Unlisted securities:				
Shares	4.189.927,64	4.189.927,64	4.189.927,64	4.189.927,64
Total	4.189.927,64	4.189.927,64	4.189.927,64	4.189.927,64

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 40 of 57

10. Other financial assets at fair value through income statement

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Listed securities:				
Mutual Funds	363.916,07	340.135,18	363.916,07	340.135,18
Unlisted securities:	None	None	None	None
Total	363.916,07	340.135,18	363.916,07	340.135,18

The mutual funds were marked to market on 31/03/2009 according to the price announced by the Fund Management Company.

11. Trade and other receivables

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Customers	27.278.559,00	28.779.117,82	2.869.321,92	1.808.449,77
Notes receivable on hand	7.307.069,08	8.550.514,35	1.828.921,55	2.633.586,14
Notes overdue	2.593.178,86	2.690.037,61	1.008.705,01	1.084.889,15
Cheques receivables	2.305.913,14	2.268.914,62	806.000,35	840.115,90
Cheques receivables overdue	255.957,14	295.262,85	97.868,77	118.108,57
Doubtful customers	2.567.158,70	2.562.189,12	2.098.775,95	2.093.806,37
<u>Less:</u> Provision for impairment of receivables	-7.441.636,36	-7.791.636,36	-3.335.563,74	-3.335.563,74
Total Receivables	34.866.199,56	37.354.400,01	5.374.029,81	5.243.392,16
Miscellaneous debtors	11.252.311,22	11.004.328,92	10.761.787,61	8.550.715,69
Down payments for purchases	78.993,25	145.486,92	77.413,24	19.151,62
Debit transit accounts	599.375,05	2.547.814,25	454.794,08	1.295.036,61
Other	224.079,51	205.998,56	24.842,15	36.472,73
Total Other Receivables	12.154.759,03	13.903.628,65	11.318.837,08	9.901.376,65

12. <u>Inventories</u>

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Consumables	5.279.129,64	5.126.075.01	2.753.862,66	2.885.708,52
Merchandise	186.451,74	163.196,16	0,00	0,00
Total	5.465.581,38	5.289.271,17	2.753.862,66	2.885.708,52

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 41 of 57

The cost of inventories for the Group recognised as expense and included in "Cost of services" and "Cost of sales" amounts to \in 12.800.658,46 in "Administrative expenses" amounts to \in 66.562,41 and in "Selling and marketing costs" amounts to \in 60.303,04 while the relevant amounts for the Company are \in 3.608.486,34, \in 23.563,92 and \in 25.039,49 respectively for the fiscal period 01.01–31.03.2009 (Note 22).

13. Cash and cash equivalents

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Cash on hand	102.684,70	42.062,20	48.534,37	2.450,88
Sight deposits	8.729.570,33	11.405.260,59	2.809.163,38	6.989.780,97
Time deposits	14.530.636,27	10.520.000,00	3.299.999,97	0,00
Total	23.362.891,30	21.967.322,79	6.157.697,72	6.992.231,85

14. Borrowings

Borrowings are recognised at actual value decreased by any direct costs for the realisation of the transaction. The analysis of the Company's and the Group's borrowings with current and non-current maturities per company at 31.03.2009 is the following:

	Current	Non-current	<u>Total</u>
IASO S.A.	2.750.000,00	69.250.000,00	72.000.000,00
IASO GENERAL S.A.	2.500.000,00	33.000.000,00	35.500.000,00
IASO THESSALIAS S.A.	0,00	18.000.000,00	18.000.000,00
Total	5.250.000,00	120.250.000,00	125.500.000,00

The analysis of the Company's and the Group's borrowings with current and non-current maturities per company at 31.12.2008 is the following:

	Current	Non-current	<u>Total</u>
IASO S.A.	5.500.000,00	66.750.000,00	72.250.000,00
IASO GENERAL S.A.	2.500.000,00	33.000.000,00	35.500.000,00
MEDSTEM SERVICES S.A.	0,00	14.500.000,00	14.500.000,00
Total	8.000.000,00	114.250.000,00	122.250.000,00

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 42 of 57

It must be noted that the matured debenture loan payments of the Group, for which there is an obligation of repayment within the current fiscal year, are not included in the Company's and the Group's long-term borrowings but are transferred to the short-term bank liabilities payable within the next fiscal year.

Long-term borrowings include the following loans that were raised during the fiscal year 2008:

- The parent company IASO S.A., on 07/11/2008, proceeded in signing a contract for the issuance of a common bond loan (revolving) up to the total amount of € 18.500.000,00. The loan has three year duration with an extension option of one plus one year. The loan will be used to finance IASO's investment and other needs which are in progress. National Bank of Greece S.A. and National Bank of Greece (Cyprus) LTD underwrote the coverage of the loan.
- The parent company IASO S.A., on 09/02/2009, proceeded in the issuance of a second bond series of total amount € 2.500.000,00, following the contract signed on 07/11/2008 for the issuance of a common bond loan with the National Bank of Greece as the organizer and bondholder representative, for the finance of the company's current investments and other needs.

The amount that has been drawn down until 31/03/2009, through the issuance of bond series expiring on 07/11/2011, is $\in 12.500.000,00$.

- The subsidiary company "IASO THESSALIAS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.", on 15/02/2008, proceeded in signing a contract for the issuance of a common bond loan up to the total amount of € 30.000.000,00 with the National Bank of Greece as the organizer and bondholder representative. The loan has eight year duration. The loan will be used to partially finance the construction of the buildings, the purchase of mechanical, biomedical and hotel equipment for the clinic's operation.
- The management of the subsidiary company "IASO THESSALIAS GENERAL CLINIC-PRIVATE OBSTETRICS S.A.", on 16/02/2009, proceeded in the issuance of a fourth bond series of total amount € 3.500.000,00, following the contract signed on 15/02/2008 for the issuance of a common bond loan with the National Bank of Greece as the organizer and bondholder representative, for the finance of the company's current investment plan and other needs. The amount that has been drawn down until today is € 18.000.000,00 and has been used for financing the company's investment plan.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 43 of 57

The amount that has been drawn down until 31/03/2009, through the issuance of four bond series, is € 18.000.000,00 and is analyzed as follows:

A' bond series, 15/02/2008, € 7.000.000,00

B' bond series, 21/05/2008, € 3.000.000,00

C' bond series, 07/11/2008, € 4.500.000,00

D' bond series, 16/02/2009, € 3.500.000,00

The first installment, including the capitalized interests, is payable on 15/02/2011 and the last one (eleventh) is payable on 15/02/2016.

The long-term balance of the debenture loans raised by the Company and the Group will be repaid through the fiscal years as follows:

	Group 31.03.2009	Company 31.03.2009
Fiscal year 2009	5.250.000,00	2.750.000,00
Fiscal year 2010	16.400.000,00	5.500.000,00
Fiscal year 2011	23.300.000,00	18.000.000,00
Fiscal year 2012	25.900.000,00	5.500.000,00
Fiscal year 2013	7.300.000,00	5.500.000,00
Fiscal year 2014	36.550.000,00	34.750.000,00
Fiscal year 2015	1.800.000,00	0,00
Fiscal year 2016	9.000.000,00	0,00
Total	125.500.000,00	72.000.000,00

14.1 Net borrowings

	Group 31.03.2009	Company 31.03.2009
Total borrowings	125.500.000,00	72.000.000,00
Cash and cash equivalents	-21.967.322,79	-6.992.231,85
Net borrowings	103.532.677,00	65.007.768,00

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 44 of 57

15. Trade and other payables

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Suppliers	40.943.520,31	38.986.218,93	9.761.243,49	6.481.020,13
Insurance and pension				
fund dues	3.021.358,95	1.380.909,77	1.978.078,52	920.032,70
Tax liabilities	2.131.609,78	961.811,19	1.447.447,51	621.058,22
Sundry creditors	2.719.572,93	4.957.619,52	5.906.926,86	3.695.036,09
Transit credit balances	3.176.922,95	6.671.822,48	1.790.480,12	4.032.400,81
Other liabilities	6.026.829,39	643.768,01	53.310,62	76.741,33
Total	58.019.814,31	53.602.149,90	20.937.487,12	15.826.289,28

There are third party lawsuits for indemnities against the Company, the Company and associated physicians as well as the Group's companies, for initial claim amounting approximately \in 52,44 mil. and \in 57,72 mil respectively. For these amounts, that mainly concern professional liability claims of associate physicians of the Group's companies alleged medical malpractice cases, no provision has been made in these financial statements of the Company and the Group. These cases according to the Group's legal departments are covered almost in full by insurance contracts for professional liability and as a result, in case that some of them do not favour the company, they will be covered by the insurance companies and consequently will not substantially affect the financial status of the Company and the Group. The aforementioned lawsuits are analysed as follows:

a. Lawsuits regarding medical malpractice

There are third party lawsuits of patients and or their inheritorsagainst the associated physicians as well as the Group's companies (IASO S.A. and IASO GENERAL S.A.) as indemnity and/or monetary compensation for moral injury, due to alleged medical "malpractice" for a total amount of approximately € 56,20 mil.

The outcome of these lawsuits is estimated not to have a material effect on the financial status of the Group's companies, since the claimed compensations are considered as extremely exaggerated and are not going to be awarded by the Greek courts, based on the heard law-cases. In case, where some of the lawsuits end up with a winning verdict, then they will be covered, totally or in large part, by the insurance companies, with which malpractice contracts have been signed, either by the Group's companies or the associated physicians.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 45 of 57

b. Other lawsuits

In addition to the aforementioned cases, there are third party lawsuits against the Group's companies (labour differences e.t.c.) for a total amount of approximately \in 1,52 mil, the outcome of these cases is estimated not to have a material effect on the financial status of the Company and the Group, respectively.

16. Retirement benefit obligations

Regarding the retirement benefit obligations, an actuarial calculation has been prepared, according to IAS 19, applying the method mentioned in § 2.15. From the said calculation arose accumulatively the following balances per company.

COMPANY	PERIOD					
	31.12.2004	31.12.2005	31.12.2006	31.12.2007	31.12.2008	31.03.2009
IASO S.A.	1.596.685,53	1.873.325,56	2.271.636,74	2.585.827,87	3.024.056,90	2.850.605,69
IASO GENERAL S.A.	994.805,66	1.167.147,46	1.514.068,82	1.518.801,13	1.709.630,45	1.616.378,26
MEDSTEM SERVICES S.A.	2.158,80	6.725,07	15.694,81	15.745,35	23.412,74	23.374,90
IASO THESSALIAS S.A.	4.754,63	3.922,18	3.922,18	3.922,18	3.922,18	3.922,18
GROUP	2.598.404,62	3.051.120,27	3.805.322,55	4.124.296,53	4.761.022,27	4.494.281,03

The total amount of the actuarial calculation, which concerns the period 01/01-31/03/2009, for the Group's personnel, amounts to \in 4.494.281,03, while for the Company's amounts to \in 2.850.605,69 respectively.

The basic actuarial assumptions adopted by all the Group's Companies that employ personnel are the following:

Assumptions	Group	Company
Discount rate (*)	From 3,20 until 4,80	From 3,20 until 4,80
Anticipated annual average increase of wages	5,00%	5,00%
Personnel's remaining labour life (**)	Depending on each employee	Depending on each employee

(*) The discount rate used, according to IAS 19, for the calculation of present values and pension payments, was determined based on the Greek state's bonds rates, which vary between 3,20% and 4,80% depending on the length of their expiry date.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 46 of 57

(**) The remaining labour life of personnel is calculated based on the declared labor life of each employee and their retirement standards, which are defined to 65 years of age for men and 60 years of age for women.

17. Other gains (profit)

	Group 31.03.2008	Group 31.03.2009	Company 31.03.2008	Company 31.03.2009
- Income from rentals	610.629,64	957.060,99	335.148,23	648.322,41
- Grants	1.875,00	67.490,00	0,00	67.490,00
- Income from side business	45.778,50	96.551,54	46.000,00	96.551,54
- Extraordinary income / expenses	10.136,06	2.595,15	10.040,55	22,19
- Income from unused prior periods provisions	83.411,31	266.703,40	82.484,45	173.451,21
-Income from property revaluation	0,00	7.633,27	0,00	0,00
- Other	5.684,02	9.733,75	7.487,08	10.113,61
Total	757.514,53	1.407.768,10	481.160,31	995.950,96

During the year 2008, the Company's management proceeded in readjusting its main contracts along with re-examining and re-organizing its most significant side businesses. As a result an important increase of revenues appeared in comparison to the previous fiscal year.

The revaluation at fair value of a plot, owned by IASO GENERAL S.A., which was conducted by independent evaluators concluded in a surplus of \in 896.000,00, which was recorded in other revenues account (income from property revaluation) in order to offset previous decrease of amount \in 2.429.311,20, which was recorded during the first appliance of the IFRS (01/01/2005).

18. Financial cost – net

	Group 31.03.2008	Group 31.03.2009	Company 31.03.2008	Company 31.03.2009
Financial cost				
- Interest expense	41.377,29	1.933,35	0,00	0,00
- Debenture loan's interests	1.498.355,61	945.649,58	764.257,73	626.293,46
- Loss from securities depreciation	197.724,06	42.467,87	197.724,06	42.467,87
- Other	4.546,89	2.578,32	2.582,28	697,88
Total Financial cost	1.742.003,85	992.629,12	964.564,07	669.459,21

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 47 of 57

Financial income				
- Credit interest	237.243,74	122.356,69	93.458,26	14.169,85
- Profit from measurement at fair				
value	0,00	0,00	0,00	18.687,18
- Dividends	0,00	0,00	0,00	0,00
- Profit from securities' sale	0,00	0,00	0,00	0,00
Total Financial income	237.243,74	122.356,69	93.458,26	32.857,03

To the subsidiary company IASO Thessalias, which has not commenced its operating activity yet, since the building of the clinic is still under construction, came up, for the 1st Quarter 2009, interests from the issuance of debenture loan, amounting to € 125.238,38. According to the new of IAS 23, the aforementioned interests which is directly related to the clinic's construction, has burdened directly the cost of construction and this is the reason why it is not included in the above table.

19. Income tax expense

	Group 31.12.2008	Group 31.03.2009	Company 31.12.2008	Company 31.03.2009
Current tax	8.427.732,66	2.140.224,45	8.073.630,89	1.834.292,61
Deferred Tax adjustments to the				
offset fiscal year	5.395.685,32	0,00	-416.891,34	0,00
Other taxes and duties	165.164,37	3.420,64	78.645,62	0,00
Deferred tax Liability/Receivable	325.559,93	178.407,52	-163.845,57	178.407,52
Tax audit adjustments	19.602,21	0,00	0,00	0,00
Provision for Tax audit adjustments	419.366,00	84.697,68	359.366,00	84.697,68
Actual tax charge	14.753.110,49	2.406.750,28	7.930.905,60	2.097.397,81
% of Actual tax charge	40,91%	25,95%	24,18%	26,05%

During the fiscal year 2008 all the Group's companies that are subjected to law 3697/2008 accepted the proposed by the Law "settlement without audit" for the unaudited fiscal years 2003-2006. On 31/12/2008, because of the lapse of the offset right of tax losses from previous fiscal years, the Company and the Group wrote off the relevant deferred tax receivables of the FY 2003, while the receivables balance on 31/12/2008, adjusted in relation to the current tax of 24% of the next fiscal year. Group's companies adjusted their tax receivables and liabilities so as, on 31/12/2008, to illustrate with clarity the Company's and the Group's equity.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 48 of 57

The Company and the Group proceeded to tax audit adjustments provision regarding the unaudited fiscal years, whose cumulative balance, on 31/03/2009, was the following:

Fiscal Year	Group	Company
2006	339.237,35	339.237,35
2007	332.903,32	332.903,32
2008	419.366,00	359.366,00
2009	84.697,68	84.697,68
Total	1.176.204,35	1.116.204,35

20. Earnings per share

Basic - Group

Basic earnings per share are calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year, excluding ordinary shares purchased by the Company and held as treasury shares.

	<u>31.03.2008</u>	<u>31.03.2009</u>
Profit attributable to equity holders of the Company	6.864.309,79	6.835.478,99
(from ongoing operations)		
Weighted average number of ordinary shares in issue (IAS 33)	53.155.053	53.155.053
Basic earnings per share	0,1291	0,1286

Basic - Company

Basic earnings per share is calculated by dividing the profit attributable to equity holders of the Company by the weighted average number of ordinary shares in issue during the year, excluding ordinary shares purchased by the Company and held as treasury shares.

	<u>31.03.2008</u>	<u>31.03.2009</u>
Profit attributable to equity holders of the Company	6.268.074,72	5.953.402,69
(from ongoing operations)		
Weighted average number of ordinary shares in issue (IAS 33)	53.155.053	53.155.053
Basic earnings per share	0,1179	0,1120

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 49 of 57

The weighted average number of ordinary shares in issue (IAS 33) at 31.03.2009 and 31.03.2008 for the Company and the Group is 53.155.053 shares respectively.

The weighted average number of shares resulted by the as of 06.06.2008 resolution of the ordinary General Meeting of Shareholders of the parent company (Note 24 of the Financial Statements) and as a result adjusted retroactively the basic earnings per share for the periods presented in the financial statements of the Company and the Group.

21. Dividends per share

The dividend paid in 2008 was € 0,33 per share, the payment was approved by the Shareholders' General Meeting held on 06.06.2008 and was demonstrated in the annual financial statements of the fiscal year 2008.

In the current fiscal year of 2009, the Company's management will propose to the Annual General Meeting of shareholders the distribution of a dividend equal to € 0,22 per share.

22. Expenses by nature

The analysis of the cost distribution, for the Company and the Group, for the fiscal periods 01.01-31.03.2009 and 01.01-31.03.2008, is the following:

	Company <u>01.01-31.03.2008</u>	Company <u>01.01-31.03.2009</u>	Group 01.01-31.03.2008	Group 01.01-31.03.2009
M 1 F C 11				
Merchandise- Consumables	12.504.661,60	12.927.523,91	3.614.849,12	3.657.089,75
Salaries and fringe benefits	10.415.550,49	11.628.654,67	6.332.403,54	7.400.706,43
Third parties' fees and expenses	7.003.101,66	7.009.030,52	4.732.348,39	4.925.844,03
Third parties' utilities and services	1.590.628,06	1.560.197,98	1.033.224,40	962.011,07
Other dues	235.111,62	229.609,24	32.195,41	78.821,35
Sundry expenses	1.139.723,00	1.285.665,65	728.770,11	794.400,63
Interest and similar charges	1.544.279,79	950.161,25	766.840,01	626.991,34
Depreciation of fixed assets charged				
to operating cost	1.854.737,74	2.201.428,35	948.183,62	1.261.391,25
Provisions	825.761,30	392.430,03	368.311,91	42.467,87
Crossing out of consolidated				
financial statements	-115.706,74	-105.022,70	0,00	0,00
Total	36.997.848,52	38.079.678,90	18.557.126,51	19.749.723,72

Page 50 of 57

The distribution of cost into cost of services, administrative cost, selling cost and financial cost of the Company for the fiscal periods 01.01-31.03.2009 and 01.01-31.03.2008 is the following:

Company 01.01-31.03.2009	Cost of services	Administrative expenses	Selling cost	<u>Financial</u> <u>expenses</u>	<u>Total</u>
Merchandise- Consumables	3.608.486,34	23.563,92	25.039,49	0,00	3.657.089,75
Salaries and fringe benefits	6.609.663,52	540.176,15	250.866,76	0,00	7.400.706,43
Third parties' fees and expenses	4.748.215,88	112.278,55	65.349,60	0,00	4.925.844,03
Third parties' utilities and services	876.397,49	45.827,95	39.785,63	0,00	962.011,07
Other dues	66.432,83	5.340,00	7.048,52	0,00	78.821,35
Sundry expenses	635.852,17	111.376,39	47.172,07	0,00	794.400,63
Interest and similar charges	0,00	0,00	0,00	626.991,34	626.991,34
Depreciation of fixed assets charged to operating cost	1.183.147,71	40.996,31	37.247,23	0,00	1.261.391,25
Provisions	0,00	0,00	0,00	42.467,87	42.467,87
Total	17.728.195,94	879.559,27	472.509,30	669.459,21	19.749.723,72

Company 01.01-31.03.2008	<u>Cost of</u> <u>services</u>	Administrativ e expenses	Selling cost	<u>Financial</u> <u>expenses</u>	<u>Total</u>
Merchandise- Consumables	3.550.165,15	22.723,76	41.960,21	0,00	3.614.849,12
Salaries and fringe benefits	5.658.270,25	434.736,70	239.396,59	0,00	6.332.403,54
Third parties' fees and expenses	4.593.154,65	91.381,73	47.812,01	0,00	4.732.348,39
Third parties' utilities and services	952.111,07	39.018,31	42.095,02	0,00	1.033.224,40
Other dues	27.414,60	2.213,89	2.566,92	0,00	32.195,41
Sundry expenses	584.140,35	103.309,97	41.319,79	0,00	728.770,11
Interest and similar charges	0,00	0,00	0,00	766.840,01	766.840,01
Depreciation of fixed assets charged to operating cost	853.573,20	52.680,15	41.930,27	0,00	948.183,62
Provisions	155.686,87	8.327,05	6.573,93	197.724,06	368.311,91
Total	16.374.516,14	754.391,56	463.654,74	964.564,07	18.557.126,51

The distribution of cost into cost of services, administrative cost, selling cost and financial cost of the Group for the fiscal periods 01.01-31.03.2009 and 01.01-31.03.2008 is the following:

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 51 of 57

Group 01.01-31.03.2009	Cost of services	Administrative expenses	Selling cost	Financial expenses	<u>Total</u>
Merchandise- Consumables	12.800.658,46	66.562,41	60.303,04	0.00	12.927.523,91
Salaries and fringe benefits	10.420.590,74	757.556,51	450.507,42	0,00	11.628.654,67
Third parties' fees and expenses	6.778.572,50	121.044,79	109.413,23	0,00	7.009.030,52
Third parties' utilities and services	1.419.662,39	77.672,16	62.863,43	0,00	1.560.197,98
Other dues	108.516,12	8.447,25	112.645,87	0,00	229.609,24
Sundry expenses	1.004.311,81	131.958,44	149.395,40	0,00	1.285.665,65
Interest and similar charges	0,00	0,00	0,00	950.161,25	950.161,25
Depreciation of fixed assets charged					
to operating cost	2.100.040,14	50.735,18	50.653,03	0,00	2.201.428,35
Provisions	-37,84	0,00	350.000,00	42.467,87	392.430,03
Crossing out of consolidated					
financial statements	-105.022,70	0,00	0,00	0,00	-105.022,70
Total	34.527.291,62	1.213.976,74	1.345.781,42	992.629,12	38.079.678,90

Group 01.01-31.03.2008	Cost of services	Administrative expenses	Selling cost	<u>Financial</u> <u>expenses</u>	<u>Total</u>
Merchandise- Consumables	12.357.044,17	66.643,98	80.973,45	0,00	12.504.661,60
Salaries and fringe benefits	9.380.193,48	614.524,19	420.832,82	0,00	10.415.550,49
Third parties' fees and expenses	6.815.904,65	117.782,36	69.414,65	0,00	7.003.101,66
Third parties' utilities and services	1.458.711,28	71.513,16	60.403,62	0,00	1.590.628,06
Other dues	73.573,12	120.307,85	41.230,65	0,00	235.111,62
Sundry expenses	890.061,93	116.517,04	133.144,03	0,00	1.139.723,00
Interest and similar charges	0,00	0,00	0,00	1.544.279,79	1.544.279,79
Depreciation of fixed assets charged to operating cost	1.738.316,86	64.060,63	52.360,25	0,00	1.854.737,74
Provisions	584.007,43	20.980,63	23.049,18	197.724,06	825.761,30
Crossing out of consolidated financial statements	-115.706,74	0,00	0,00	0,00	-115.706,74
Total	33.182.106,18	1.192.329,84	881.408,65	1.742.003,85	36.997.848,52

23. Guarantees

The Group has liabilities to banks, other guarantees and other matters that arise from its activity. The parent company at 31.03.2009 has granted guarantees to banks for the amount of \notin 75 million, in favour of its subsidiaries.

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 52 of 57

24. Share capital

	Number of shares	Share's nominal value	Value of ordinary shares	Above par value	Total
1 st of January 2009	44.075.500	0,53	23.360.015,00	42.525.668,15	65.885.683,15
Share capital increase	44.075.500	0,00064	28.208,32	-28.208,32	0,00
Share capital decrease	9.079.553	0,44	0,00	0,00	0,00
31st of March 2009	53.155.053	0,44	23.388.223,32	42.497.459,83	65.885.683,15
Weighted average number of					
shares according to IAS 33	53.155.053	0,44	23.388.223,32	42.497.459,83	65.885.683,15

25. Other long-term receivables

Other long-term receivables of the Company and the Group are presented as follows:

	Gr	oup	Company	
Guarantees	31.12.2008	31.03.2009	31.12.2008	31.03.2009
Public Power Corporation	82.060,00	82.060,00	49.360,00	49.360,00
O.T.E.	269,99	2.435,20	269,99	269,99
E.Y.D.A.P.	5.922,63	5.922,63	5.491,00	5.491,00
Medical gas	13.217,58	14.575,58	13.191,17	13.191,17
Buildings	17.929,64	17.963,30	0,00	0,00
Vehicles	14.944,09	15.212,09	6.619,88	7.435,88
Other long-term receivables	671.417,42	713.226,74	0,00	0,00
Total	805.761,35	851.395,54	74.932,04	75.748,04

All the above given guarantees, either to public or to private organisations, concern the operation of the Company and the Group's companies and are claimable at the expiry date of their respective contracts.

Other long-term receivables are recorded in the following fiscal years, when accrued, and mainly concern the operation of the stem cells collection and storage of the subsidiary company "MEDSTEM SERVICES S.A.".

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 53 of 57

26. Other non-current liabilities

Other non-current liabilities of the Company and the Group are presented as follows:

	Gro	up	Company	
	31.12.2008	31.03.2009	31.12.2008	31.03.2009
Received rent guarantees	78.495,63	82.995,63	68.854,75	73.354,75
Unearned and deferred income	4.476.116,13	4.754.845,02	0,00	0,00
Total	4.554.611,76	4.837.840,65	68.854,75	73.354,75

The subsidiary "MEDSTEM SERVICES S.A.", storages cord blood stem cells and precollects deferred income. This policy creates long-term liabilities which expire along with the twenty year contracts. The aforementioned long-term revenues will be measured within the period that the above services will be offered.

27. Other non-current provisions

The other non-current provisions refer to the Company's calculated provisions which overcome a fiscal year.

28. Other operating expenses

	Gro	up	Company	
	31.12.2008	31.03.2009	31.12.2008	31.03.2009
Non-operating expenses	3.173,92	1.439,90	2.379,51	1.248,61
Losses of fixed assets	5.397,92	13.761,51	5.397,92	0,00
Prior period expenses	480.804,60	263.952,30	10.792,45	0,00
Provisions for extraordinary contingencies	0,00	0,00	0,00	0,00
Total	489.376,44	279.153,71	18.569,88	1.248,61

Page 54 of 57

29. Reserves at fair value - Other reserves

	Gr	oup	Company		
	31.12.2008	31.03.2009	31.12.2008	31.03.2009	
Land	34.239.041,03	34.239.041,03	11.274.658,79	11.274.658,79	
Buildings	31.517.452,40	31.517.452,40	29.567.607,76	29.567.607,76	
Reserves at fair value Total	65.756.493,43	65.756.493,43	40.842.266,55	40.842.266,55	
Legal Reserve	6.975.781,65	6.975.781,65	6.480.570,89	6.480.570,89	
Other Reserves Total	6.975.781,65	6.975.781,65	6.480.570,89	6.480.570,89	

For the cumulative surplus value deriving from the property adjustment to fair value that is demonstrated in the consolidated financial statements of 31/12/2008, was calculated, within the fiscal period, deferred tax liability with estimated tax rate 20% because of the long-term self use of property. As a result the equity of the Company and the Group was decreased by $\in 10,2$ mil. and $\in 16,44$ mil. respectively.

This deferred liability of the Company and the Group was calculated with tax rate 20%, since, according to law 3697/2008 (that was published in 2008) the tax rate for the fiscal years 2010-2014 will be reduced by 1 point per fiscal year.

Other reserves, include the Company's and the Group's legal reserve, which is assessed by the Annual General Meeting's approval of the profits' distribution.

30. Events after the balance sheet date

On 26/05/2009, the management of the parent company announced that it was signed between the subsidiary IASO of SOUTHERN SUBURBS S.A. and INTRAKAT S.A. a preliminary contract regarding the purchase of a piece of land of 12.680 m² in the municipality of Agios Ioannis Redis, which belongs to INTRAKAT. The preliminary contract was signed in execution of the relevant term of 19/03/2009 memorandum of cooperation, for the construction of a clinic by INTRAKAT. The budget of this project comes up to 70 million euros and the clinic will have a total capacity of 160 nursing beds and about 40 beds for special units.

At the Extraordinary General Meeting of shareholders of the subsidiary company IASO Thessalias it was decided to increase the company's share capital by the amount of € 5.493.324,00 through cash payment, by the issuance of 2.746.662 new common registered shares of nominal value € 2,00 and issue price € 3,50 per share and cancellation of the

"IASO" PRIVATE GENERAL – OBSTETRIC – GYNECOLOGICAL & PAEDIATRICS CLINIC – DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 55 of 57

existing shareholders' preference right along with the relevant amendment of article 3 of the company's articles of association.

Maroussi, 27/05/2009

CHAIRMAN OF THE GROUP'S CHIEF GROUP'S CHIEF BOARD OF DIRECTOR MANAGING DIRECTOR FINANCIAL OFFICER ACCOUNTING OFFICER

IOANNIS CH. ZOLOTAS GEORGIOS I. STAMATIOU ANASTASSAKIS TSIROPOULOS

I.D.: A 005562 I.D.: K 030874 I.D.: AA 58349 I.D.: T 123040

A' CLASS REG. No 21907

Page 56 of 57

F. DATA AND INFORMATION FOR THE PERIOD JANUARY 1st TO MARCH 31st 2009

IASO S.A.

PRINATE GENERAL-OBSTETRIC-GYNECOLOGICAL & PAEDIATRICS CLINIC-DIAGNOSTIC-THERAPEUTIC & RESEARCH CENTER REQ. No : 13366/06/B/86/61 REQ. No : 13366/06/B/86/61 37-39 Kiffissias Ave. 15123 Maroussi Athens Data and Information for the period 1 January 2009 to 31 March 2009 (Published in accordance with Decision 4/507/28.042009 of the Board of Directors of the Hellenic Capital Market Commission)

ral briefing for the financial position and the results of operations of the Group and the Company IASO S.A. . Therefore, it is recommended, ansaction with the Company, to visit the Company's web site, where the Financial Statements are posted and prepared according to the to of the Certified Auditor Accountant where it is necessary.

1. STATEMENT OF FINANCIAL POSITION (consolidated and company)				
emounts reported in Euro) THE GROUP THE COMPANY.				
ASSETS	31/3/2009	31/12/2008	3 1/3/2009	31/12/2008
Tangible assets	268.930.670,52	261,990,376,40	129.855.457,64	129,530,544,09
Intengible assets	1.485.663,37	1.556.846,35	976.638,52	1.012.669,45
Other non-current assets	851,395,54	805.761,35	124.561.479,40	122,060,662,40
invertories	5.289.271,17	5.465.581,38	2.885.708,22	2,753,862,66
Trade and other receivables	37.354.400,01	34,866,199,56	5.243.392,16	5.374.029,81
Other current assets	40.401.014,46	40.071.494,04	21.423.671,52	22,030,378,51
TOTAL ASSETS	354.312.415.07	344.758.259,08	284.946.347,46	282.762.146,92
	TH	EGROUP	THE	OMPANY
EQUITY AND LIABILITIES	31/3,2009	31/12/2008	31/3/2009	31/12/2008
Shareholders Equity (53.155.053 shares x 0,444)	23.388.223,32	23.388.223,32	23.388.223,32	23,388,223,32
Other shareholders equity	103.717.860,28	97.178.645,79	145.445.680,42	139.492.277,73
Total Shareholders Equity (s)	127.106.083,60	120.566.869,11	168.833.903,74	162.88 0.50 1,05
Minority interests (b)	11.900.220,85	9.798.981,32	0,00	0,00
Total Equity (c) =(a) +(b)		130.365.860,43	168.833.903,74	
Long-term Bank borrowings	120.250.000,00	114.250.000,00	69.250.000,00	66.750.000,00
Provisions/Other long-term list littles	25.865.950,06	25.692.861,68	18.378.230,94	18.620.527,86
Shor Herm Bank borrowings	5.250.000,00	8.000.000,00	2,750,000,00	5.500.000,00
Other short-term liabilities	63.940.160,56	68.447.546,97	25.734.212,78	29.011.118,01
Total Liabilities (d)		214.390.408,64	116.112.443,72	
TOTAL EQUITY AND LIABILITIES (e)=(c)+(d)	35431241507	344.756,259,06	284,946,347,46	282,762,146,92
2. STATEMENT OF COMPREHENSIVE INCOME	(consolidated	and company)		
(Amounts reported in Euro)	714	EGROUP	740	OMPARY
(Autorità Laborità III Caro)	1/1-31/3/2009		1/13/13/2009	1/1-31/3/2008
Skins	46,103,235,62	45.823.518.66	26,772,964,84	26,474,836,53
Gross profit/(cas)	11.575.943.99	12.641.412.48	9.044.768.90	10,100,320,39
Earnings/(cas) before taxes, frencing				
and investing results (EBIT)	10.144.800.23	10.835.812.08	8.687.402.68	9.344.884.52
Profit (kas) before taxes	9.274.527.80	9.331.051.97	8.050.800.50	8.473.758.71
Profit/(loss) after taxes (A)	6.867.777.51	6,881,044,67	5.953,402,69	6,268,074,72
Atributable to:			***************************************	
Equity holders of the Company	6.835.478.99	6.864.309.79	5.953.402.69	6.268.074.72
Minority interest	32,298,53	16,734,87		
Other Comprehensive Income after taxes (B)	0.00	0.00	0.00	0.00
Total Comprehensive Income after taxes (A)+(B)	6.867.777.51	6.881.044,67	5.953,402,69	6.268.074.72
Atributable to:	- mmmir tomo		THE PARTY OF THE P	municipality of the
Equity holders of the Company	6.835,478,99	6.864.309.79	5.953.402.69	6.268.074.72
Minority interest	32,298,53	16,734,87		
Earnings/(basi) after taxes per share - basic (expressed in 4)	0,1286	0,1291	0,1120	0,1179
Earnings/(loss) before taxes, financing and investing	-			
results and depreciation-amortisation (ESITDA)	12,346,228,58	12,690,549,82	9.948,793,93	10,293,048,14
3. STATEMENT OF CHANGES IN EQUITY (const				
(Amounts reported in Euro)		EGROUP		OMPANY
	31/3/2009	3 1/3/2008	31/3/2009	31/3/2008
Net eguity of period Opening Balance				

4. CASH FLOW STATEMENT (consolidated and				
(Amounts reported in Euro)		LOROUP		OMPANY
Cash Rows from Operating Activities	1/1-3 1/3/2009	1/1-31/3/2008	1/1-31/3/2009	1/1-31/3/2008
Not Profit hefore tores	9.274.527.80	9.331.051.97	8,050,800,50	8.473.758.71
Plus/Lens adjustments for:	9214021,00	2.001.001,01	0.000 200,00	G-41-32-32-3
Depreciation and amortisation	2.201.428.35	1.864.737.74	1,261,391,25	948,183.62
Provisions	2.186.497.95	2.511.803.65	1.164.405.71	1.094.970.89
Interest charges and other related expenses	992,629,12	1,742,003,85	669,459,21	964,564,07
Results (revenue, expenses, profit and loss)				
from investment activity	-111.091,18	-237 2 43,74	-32.857,03	-93.468,26
Other adjustments	-70.910.64	5,378,05	-87.490,00	5.378,05
	14,473,081,40	15,207,73 1,52	11,045,709,64	11,393,397,08
Plus/Less adjustments of working capital				
to not cash or related to operating activities:				
Decrease/(increase) of inventories	176.310.21	-148.567,42	-131.845,56	73.868,25
Decresse/(Incresse) of Receivables	2.911.659,65	-1.141.361,32	-113.834,39	-700.165,92
(Decrease)/Increase of payable accounts (except Banks)	7.603.856,82	-7.529.048,36	-6.737.374,52	-3.458.925,19
Lance				
Interest paid and similar expenses	-1.156.620,20	-2.013.811,95	-1.073.046,41	-1.236.372,17
Income Tax paid	-173.974,14	-165.425,59	-164.854,14	-165.425,59
Decresse/fincresse) of other current assets accounts	-3 12,720,52	-750.504,65	-273.445,67	-100.369,86
Net cash generated from Operating Activities (a)	2.490.580,28	3.469.012,23	2.551.308,95	5.806.006,60
Cash Flows from Investing Activities				
Purchases of subsidiaries, associates,				
pirt-ventures and other investments	0,00	108.729,60	-1,00	-4.295.408,68
Purchases of tangible and intangible assets	-0.088.105,00	-5.323.022,97	-1.550.273,87	-202,813,19
Proceeds from sale of tangible and intangible assets	6.300,00	5.398,72	0.00	5.398,72
Interest received	103.669,51	237 2 43,74	14.169,85	93.468,26
Proceeds from grants	69,665,00	0,00	69.685,00	00,0
Net cash generated from Investing Activities (b)	-8.908.A70,49	-4.971.650,91	-1.466.440,02	-4.399.364,89
Cash Rove from Regarding Activities				
Proceeds from share capital increase	1,772,676,50	121,833,22	0.00	000
Proceeds from issued/aised loans	6,000,000,00	7.000.000.00	2,500,000,00	000
Recovered of borrowings	2.750.000.00	-526.492.62	-2.750.000.00	000
Dividenda peld	-334.80	-14.327.33	-334.80	-14.327.33
Net cash generated from Financing Activities (c)	5.022.341,70	6.581.013.27	-250,334,80	-14.327,33
Net horeme/(decrease) In cash and				
cash equivalents (a) + (b) + (c)	-1.395.568,51	5.068.374,59	834.534,13	1.392.314,38
Cash and cash equivalents at beginning of parted	23.362.891,30	27.443.241,60	6.157.697,72	12.486.263,90
Cash and cash equivalents at end of parted	21.967.322.79	32,511,616,19	6.992.231.85	13.878.578.28

DITIONAL DATA AND INFORMATIO

The Companies of the Group with respective address and participation percentages that are included in the consolidated Financial Statements (Note 8.2) are:					
Full Consolidation Method.					
COMPANY NAME		Reclatered Office	Unaudited fiscal years	% of participation	Participation relationship
1. IASO SA		Greece, Marcussi, Atiki	2006-2008		Parent
2. IASO GENERAL CLINIC OF HOLARGE	06 SA	Greace, Holergos, Attiki	2006-2008	97,07%	Direct
3. IASO MACEDONAS HEALTH GROUP	OF NORTHERN GREECE SA	Greece, Marcussi, Attiki	2007-2008	100,00%	Direct
4. IASO OF SOUTHERN SUBURBS GEN	ERAL CLINIC-PRIVATE OBSTETRICS SA	Greece, Marcussi, Attiki	2007-2008	53,43%	Direct & Indirect
5. MODERN MULTIFUNCTIONAL REHAB	SILITATION-RESTORATION CENTER SA	Greece, Marcussi, Attiki	2007-2008	99,97%	Direct & Indirect
6. IASO HEALTH ENTERPRISES SA		Greece, Marcussi, Attiki	2007-2008	99,97%	Direct & Indirect
7. MEDISTEM SERVICES SA		Greece, Marcussi, Attiki	2007-2008	99,97%	Direct & Indirect
8. IASO THESSALIAS GENERAL CLINIC	-FRIVATE OBSTETRICS SA	Greece, Lartssa	2007-2008	71,20%	Direct & Indirect

120.000.304.45 127.329.629.29 100.839.300.74 129.104.047.47

	according to IAS 24, are as follows:						
		Group	Company				
	a) Revenues	00,0	65.539,06				
	b) Experses	54.812,00	96.758,64				
	c) Receivables	00,0	175.358,38				
	d) Liebilities	0,00	7.758,00				
	 e) Remuneration to BoD members and managers 	264.415,31	264.415,31				
	f) Receivables from BoD members and managers	00,0	0,00				
	g) Payables to BoD members and managers	0,0	0,00				
Marounal, 27 May 2000							
	CHARMAN OF THE BOARD OF DIRECTORS	MANAGING DIRECTOR	GROUPS CHIEF RNANCIAL OFFICER	CHIEF ACCOUNTING OFFICER			
	IOANNIS CH. ZOLOTAS	GEORGIOS I. STAMATIOU	VASSILIOS E. ANASTASSAKIS	STYLIANOS D. TSIROPOULOS			
	I.D. : A 005862	LD.: K 030674	I.D.: AA 58349	I.D.: T 123040 A' CLASS REG. No 21907			

"IASO" PRIVATE GENERAL - OBSTETRIC - GYNECOLOGICAL & PAEDIATRICS CLINIC - DIAGNOSTIC - THERAPEUTIC & RESEARCH CENTER S.A.

Page 57 of 57